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Disclaimer
The information set out in this publication is current at the date of first 
publication and is intended for use as a guide of a general nature only and 
may or may not be relevant to particular patients or circumstances. Nor 
is this publication exhaustive of the subject matter. Persons implementing 
any recommendations contained in this publication must exercise their 
own independent skill or judgement or seek appropriate professional 
advice relevant to their own particular circumstances when so doing. 
Compliance with any recommendations cannot of itself guarantee 
discharge of the duty of care owed to patients and others coming into 
contact with the health professional and the premises from which the 
health professional operates.
While the text is directed to health professionals possessing appropriate 
qualifications and skills in ascertaining and discharging their professional 
(including legal) duties, it is not to be regarded as clinical advice and, 
in particular, is no substitute for a full examination and consideration of 
medical history in reaching a diagnosis and treatment based on accepted 
clinical practices.
Accordingly The Royal Australian College of General Practitioners 
and its employees and agents shall have no liability (including without 
limitation liability by reason of negligence) to any users of the information 
contained in this publication for any loss or damage (consequential 
or otherwise), cost or expense incurred or arising by reason of any 
person using or relying on the information contained in this publication 
and whether caused by reason of any error, negligent act, omission or 
misrepresentation in the information.
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Introduction
The review and updating of the first (2005) edition of the National guide to a 
preventive health assessment for Aboriginal and Torres Strait Islander people 
(‘National Guide’) is a joint initiative of the National Aboriginal Community 
Controlled Health Organisation (NACCHO) and The Royal Australian College of 
General Practitioners (RACGP) National Faculty of Aboriginal and Torres Strait 
Islander Health. The National Guide is a practical resource intended for all health 
professionals delivering primary healthcare to Aboriginal and/or Torres Strait 
Islander people. Its purpose is to provide GPs and other health professionals 
with an accessible, user-friendly guide to best practice in preventive healthcare 
for Aboriginal and Torres Strait Islander patients.
This second edition of the National Guide comprises:
•	 the National Guide, which contains evidence statements, recommendations, 
risk calculation tables and an outline of the development of the guide
•	 the evidence base: the collection of evidence underpinning the guide and 
recommendations (e-version only) (see the Methodology section ‘Searching 
the evidence base and drafting recommendations’)
•	 a child and adult lifecycle summary chart listing activities recommended at 
each age group.
The National Guide is available on the NACCHO and the RACGP websites at 
www.naccho.org.au and at www.racgp.org.au/aboriginalhealth/nationalguide.
Note: This print version of the National Guide does not include the evidence or 
preamble to a topic (see the full e-version for the evidence base).
The National Guide is being integrated into clinical software over time to support 
primary healthcare professionals to implement best practice by providing them 
with accessible, accurate and up-to-date preventive health information relevant 
to Aboriginal and Torres Strait Islander people. For further information contact 
the RACGP National Faculty of Aboriginal and Torres Strait Islander Health on 
03 8699 0499 or email aboriginalhealth@racgp.org.au. 
Purpose
The National Guide is intended for all health professionals delivering primary 
healthcare to the Aboriginal and Torres Strait Islander population. This includes 
general practitioners (GPs), Aboriginal and Torres Strait Islander health workers, 
nurses and those specialists with a role in delivering primary healthcare. The 
National Guide makes specific recommendations regarding the elements of a 
preventive health assessment across the lifecycle of the Aboriginal and Torres 
Strait Islander population.
The aim of the National Guide is to provide an up-to-date, evidence-based 
national resource that can help inform health providers and policy makers on a 
defined set of activities that are of particular relevance to Aboriginal and Torres 
Strait Islander people.
These activities may prevent disease, detect early and unrecognised disease, and 
promote health in the Aboriginal and Torres Strait Islander population while allowing 
for variations based on regional and local circumstances. The health status of 
Torres Strait Islander people is very similar to that of the Aboriginal population, and 
the information in the National Guide can be applied to both population groups.
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How to use the guide
Using the recommendations
All health professionals delivering primary healthcare to Aboriginal and/or Torres 
Strait Islander patients should use the recommendations to enhance the clinical 
care they provide. The National Guide aims to complement the RACGP Guidelines 
for preventive activities in general practice (the ‘red book’) by dealing with health 
issues that are specific to the Aboriginal and Torres Strait Islander population.
Cross referencing with the RACGP red book
The chosen subject areas in the National Guide represent the key health issues that 
are amenable to primary healthcare intervention and contribute to morbidity and 
mortality in the Aboriginal and Torres Strait Islander population. Where issues common 
in the general Australian population have not been dealt with in this guide (eg. urinary 
incontinence), GPs are encouraged to cross-reference with the red book, which is 
available on the RACGP website at www.racgp.org.au/guidelines/redbook. The red 
book is a synthesis of evidence-based guidelines from Australian and international 
sources and provides recommendations for everyday use in general practice.
Using local guidelines
Healthcare providers (particularly in regional and remote areas) are also 
encouraged to refer to local guidelines, where appropriate and available, in order 
to optimise preventive health assessments. Many of the recommendations in the 
National Guide describe health problems that may be of concern only in certain 
regional areas. For example, trichiasis screening is only appropriate for an elderly 
Aboriginal patient who was raised in a trachoma endemic area (see Chapter 6: Eye 
health). Consequently, many recommendations highlight the importance of clinical 
discretion in decision making.
Appraising current preventive practice
Healthcare providers should use the National Guide to systematically appraise 
current preventive practice, especially where recommendations for the general 
population have previously been applied to Aboriginal and Torres Strait Islander 
patients. Providers may also benefit by appraising certain screening activities for 
which there are ‘good practice points’ (ie. expert opinion based recommendations 
but little current evidence). Inappropriate preventive interventions may draw 
resources away from activities known to improve the health of the Aboriginal and 
Torres Strait Islander population, such as risk factor modification and immunisation 
programs.
Why preventive health assessments are necessary
A systematic and comprehensive approach to prevention
There is strong evidence that the delivery of clinical preventive health services 
improves health outcomes. These services include immunisation, screening for 
asymptomatic disease, chemoprophylaxis (using medication to prevent the onset of 
disease), counselling and other ways to encourage patient behavioural change, as 
well as primary healthcare influences over environmental factors. 
See the Methodology section ‘Developing recommendations’.
Opportunity to improve Aboriginal and Torres Strait Islander health equality
Primary care providers often miss opportunities for the prevention of chronic 
disease and associated complications in the Aboriginal and Torres Strait Islander 
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population, and miss opportunities to identify if patients are of Aboriginal and/or 
Torres Strait Islander origin. 
Health service utilisation data indicate that Aboriginal and Torres Strait Islander 
people are high users of publicly provided services such as public hospitals and 
community health services and low users of medical, pharmaceutical, dental and 
other health services that are, for the most part, privately provided.1
Overall, in 2008–09, the potentially preventable hospitalisation rate for Aboriginal 
and Torres Strait Islander people (14 564 per 100 000 population) was 4.9 times 
the rate for other Australians (2956 per 100 000).2 Potentially preventive chronic 
diseases and injury are conditions causing the greatest proportion of excess 
deaths for Aboriginal and Torres Strait Islander people.3
Despite the overall health needs being higher for Aboriginal and Torres Strait 
Islander people, in 2008–09, average Medicare Benefits Schedule (MBS) 
expenditure per person was $363 for Aboriginal and Torres Strait Islander 
people and $621 for non-Indigenous Australians, a ratio of 0.58.1 The average 
Pharmaceutical Benefits Schedule (PBS) expenditure per person was $250 
for Aboriginal and Torres Strait Islander people and $338 for non-Indigenous 
Australians, a ratio of 0.74.1
When preventive opportunities are missed, this can lead to a higher dependency 
on hospital care, which increases health costs. The Aboriginal and Torres Strait 
Islander population has much higher rates of hospital admission for almost 
every health problem than other Australians.2 Consequent life expectancy is 
much lower – Aboriginal and Torres Strait Islander males in 2005–07 had a life 
expectancy of 67 years, 11.5 years fewer than non-Indigenous males2 (based 
on the Australian Bureau of Statistics revised ‘direct method’ to account for the 
under-identification of Aboriginal and Torres Strait Islander deaths adopted in 
2009). 
Return on investment
Many chronic diseases within the Aboriginal and Torres Strait Islander population 
are unrecognised by patients. This has been well documented for diseases 
known for their insidious onset, such as diabetes, hypertension, cardiovascular 
disease and chronic renal failure. The preventive approach requires the ‘service to 
seek the patient’ while the patient is asymptomatic. It involves activity for primary 
prevention (to prevent the onset of disease), secondary prevention (to detect 
preclinical disease for cure or prevention of disease progression) and to a less 
extent, tertiary prevention (to minimise the consequences for those who already 
have disease). Preventive health assessments also involve the assessment of 
comorbidities in patients who already have a chronic disease.
The preventive approach to health has shown return on investment in non-
Indigenous Australians, especially federal expenditure on immunisation, public 
health campaigns and the incorporation of preventive measures into primary 
care.4 Aboriginal and Torres Strait Islander people have a significant capacity 
to benefit from preventive healthcare. Given the reduced access to preventive 
healthcare by Aboriginal and Torres Strait Islander people and the huge burden 
of undiagnosed disease, effort needs to focus on measures to ensure that 
Aboriginal and Torres Strait Islander patients who are symptomatic of disease, 
as well as those who do not yet know they have disease (subclinical), have 
access to help.
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Identifying Aboriginal and Torres Strait Islander patients
Implementing preventive health assessments requires healthcare providers to 
identify the target population. Research shows that where general practices 
take systematic action to improve their identification processes, there is 
a corresponding increase in the number of correctly identified patients.5 
Identifying Aboriginal and Torres Strait Islander status is a necessary 
precondition for participating in the Closing the Gap initiative, agreed by the 
Australian Government and the Council of Australian Governments in 2008.6 
Without practice awareness, a patient who is of Aboriginal and/or Torres Strait 
Islander origin cannot benefit from the measures in the Australian Government’s 
Indigenous Chronic Disease Package.6 These include key measures available 
under the Practice Incentives Program Indigenous Health Incentive and PBS 
Co-payment Measure. For more information see www.medicareaustralia.gov.au/
provider/incentives/pip/forms-guides.jsp#N10068.
The RACGP paper, Identification of Aboriginal and Torres Strait Islander 
people in Australian general practice, assists health professionals in identifying 
Aboriginal and Torres Strait Islander patients; this is available at www.racgp.org.
au/aboriginalhealth.5
All health professionals have an important role in facilitating the identification of 
Aboriginal and Torres Strait Islander patients. In order for a person to identify as 
being Aboriginal and/or Torres Strait Islander and accept this being recorded 
on their medical records, a culturally supportive and culturally safe environment 
needs to be established and continuously demonstrated. Several guidelines 
have been developed to assist GPs with this issue.5,7,8
Implementing preventive health interventions
Most preventive interventions are efficiently delivered opportunistically in the clinical 
encounter where primary healthcare services are available. Others are delivered 
through integrated approaches between primary healthcare providers and other 
services such as in the planning and delivery of breast cancer screening.
Using multiple strategies
Implementing preventive health assessment and interventions ideally involves 
strategies for both patients and healthcare providers. Usually multiple strategies 
are most effective, as exemplified by those used to increase adult vaccination 
(see Chapter 11: Respiratory health). These strategies may include opportunistic 
screening (case finding) and reminder systems within clinic settings, as well as 
outreach programs such as vaccination in non-traditional settings.
A preventive assessment may be undertaken in a single session between patient 
and health provider, which may or may not simultaneously address other concerns 
the patient may have, or be delivered incrementally over a number of sessions. 
Whether clinic based or community based, systems used to deliver a preventive 
assessment need to support a holistic assessment of the patient in recognition of 
the interdependence of many risk factors and determinants of disease.
Undertaking interventions
A preventive health assessment should be undertaken by healthcare providers 
who have the capacity to undertake, or to arrange for, appropriate management 
of any abnormalities found during the assessment. Providers should be aware 
of the potential psychosocial impact of preventive care, particularly when 
screening results in the diagnosis of a new condition. Informed consent should 
5National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
be obtained for the screening and adequate counselling provided when the 
patient is advised of the result.
Appropriate health policies
A supportive health policy is critical to implementing a preventive health 
assessment. Examples include financial incentives and workforce support. 
Those who have been screened need to be treated, so an effective screening 
program will increase the demand for care, yet many health services for 
Aboriginal and Torres Strait Islander people are under-resourced. Plans to 
reduce premature and excess Aboriginal and Torres Strait Islander morbidity 
and mortality need to include investment in the management of previously 
unrecognised diseases.
Medicare and the Practice Incentives Program Indigenous Health Incentive 
General practitioners may undertake preventive activities recommended in 
the National Guide as part of their usual consultations. Medicare benefits are 
payable for a medical examination or test on a symptomless patient by that 
patient’s own medical practitioner in the course of normal medical practice, 
to ensure the patient receives any medical advice or treatment necessary to 
maintain his/her state of health.
Medicare rebates for preventive health assessments are available for all 
Aboriginal and/or Torres Strait Islander people of any age through an annual 
health assessment (Medicare Item 715). General practitioners are advised to 
check the requirements in the current online MBS before claiming these items. 
They need to be aware of, and comply with, the requirements of the specific 
MBS descriptors when providing services. The National Guide contains advice 
on almost all elements of the requirements to claim this rebate. 
Other MBS rebates can support preventive health assessments of the 
Aboriginal and Torres Strait Islander population, including:
•	 telehealth rebates (eg. item 2100)
•	 follow up assessments by allied health professionals including Aboriginal and 
Torres Strait Islander health workers (AHWs) across Australia (eg. item 81300) 
or AHWs in the Northern Territory only or practice nurses (eg. item 10987)* 
•	 follow up of GP management plans by AHWs across Australia (eg. item 
10950) or AHWs in the Northern Territory only (eg. item 10997)*
•	 immunisation by AHWs in the Northern Territory only (eg. item 10988)*
•	 antenatal services in RRMA 3–7 areas by AHWs in the Northern Territory 
only* (or midwives/nurses) (eg. 16400).
In addition, preventive health assessments can be supported through ‘CTG’ 
scripts, which provide copayment relief for PBS prescriptions for patients 
who identify as Aboriginal and/or Torres Strait Islander. Health services can 
also receive incentive payments for identifying Aboriginal and/or Torres Strait 
Islander patients and offering these patients a health assessment. The Practice 
Incentives Program is outlined at www.medicareaustralia.gov.au/provider/
incentives/pip/index.jsp.
*  Check MBS eligibility requirements. The Australian Health Practitioner Regulation Agency is 
currently nationally registering Aboriginal and Torres Strait Islander health practitioners, which 
may affect the eligibility of AHWs (those not registered as ‘practitioners’) to claim MBS rebates, 
while broadening eligibility for practitioners. 
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Key changes to existing chapters
Topic Key changes
Smoking New recommendations include assessing smoking status regularly, assessing level of nicotine 
dependence and implementing a system to identify all smokers and document tobacco use
Overweight/obesity New behavioural recommendations for overweight/obese people including assessing the risk/
benefit of orlistat and bariatric surgery, and the need to advocate for community based interventions 
to increase access to healthy food
Physical activity New behavioural recommendations for people that are insufficiently active, have diabetes and/or 
cardiovascular disease. Levels of physical activity align with the Australian National Physical Activity 
Guidelines 2010
Alcohol New recommendations include screening for hazardous drinking in high risk groups, considering 
screening for people 10–14 years and advising women to limit their alcohol intake to no more than 
2 standard drinks/day if they choose to drink while breastfeeding. Health professionals to promote 
community-led strategies to reduce alcohol supply
Child health Includes a significant number of key changes under immunisation, anaemia, growth failure and 
childhood kidney disease
Dental health New recommendations include non-dental professionals undertaking oral health reviews in addition 
to regular dental health professional reviews, application of fluoride varnish for 0–5 year olds, and 
antibiotic prophylaxis prior to dental procedures for people at high risk of endocarditis. Health 
professionals to advocate for fluoridation of the community water supply 
What’s new in the second edition? 
The format of the second edition of the National Guide has been significantly revised to 
give some structure to the different types of preventive activities delivered by primary 
healthcare providers. All the evidence underpinning the recommendations is included 
in the preamble to the recommendations, which is available at www.racgp.org.au/
aboriginalhealth/nationalguide.
The format of the National Guide is now also better aligned with the RACGP red book. 
The guide aims to complement the red book by dealing with health issues that are specific 
to the Aboriginal and Torres Strait Islander population. Where issues common in the 
general Australian population have not been dealt with in this National Guide (eg. urinary 
incontinence), health professionals are encouraged to cross reference with the red book, 
which is available on the RACGP website at www.racgp.org.au/guidelines/redbook. 
New chapters
Topic Scope
Gambling Recommends interventions to prevent gambling related harms: the identification and management of 
problem gambling and gambling prevention strategies including community activities
The health of young 
people
Focuses on three key preventive health issues for young people: psychosocial assessment, unplanned 
pregnancy and illicit drug use
Rheumatic heart 
disease
Provides recommendations for all people in addition to those with a history of acute rheumatic fever/
rheumatic heart disease and communities where Group A streptococcal infections are common and 
acute rheumatic fever is prevalent
Antenatal care Focuses on five key preventive health issues for pregnant women: general assessment at the first 
antenatal visit, smoking cessation, alcohol consumption, genitourinary and bloodborne virus infections 
and nutritional assessment and supplementation
Mental health Focuses on screening for depression and suicide prevention
Preventive health for 
the elderly
Focuses on three key preventive health issues for elderly people: osteoporosis, falls and dementia
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Eye health New recommendations for eye examinations and visual acuity assessments throughout the lifecycle 
as well as specialised assessments for people with cataracts or diabetes. Advice for smokers and 
reducing ocular exposure to UV-B light to reduce cataracts
New trachoma and trichiasis recommendations for those in trachoma endemic areas include 
community screening programs, eye examinations for adults >40 years and prevention and control 
strategies. Assessing housing situations for overcrowding and providing support is also relevant for 
people outside of trachoma endemic areas
Hearing loss New recommendations include various vaccinations for children aged <15 years and 
pregnant women, providing hearing screening throughout the lifecycle, and new behavioural, 
chemoprophylaxis and environmental recommendations
Sexual health and 
bloodborne viruses
Adds general prevention advice that includes behavioural and environmental recommendations 
and screening for chlamydia, gonorrhoea, trichomonas vaginalis, syphilis and hepatitis B. Updated 
immunisation advice has been included for hepatitis B, human papilloma virus, hepatitis A, hepatitis 
C and human immunodeficiency virus
Respiratory health This chapter focuses on five key preventive respiratory health issues: pneumococcal disease, 
influenza, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and suppurative 
lung disease. Asthma, bronchiectasis and suppurative lung disease are new topics
New recommendations for influenza prevention, encouraging good hygiene practice and minimising 
exposure risk for healthcare workers. Other changes include consideration of chemoprophylaxis 
for people at high risk of influenza complications and community based strategies to improve 
vaccination uptake
New recommendations for pneumococcal disease prevention include promotion of strategies 
to improve pneumococcal vaccination uptake such as reminder/recall systems and community 
awareness
New recommendations for COPD include offering vaccination, screening for symptoms of COPD, 
discussing smoking cessation and minimising other risk factors for COPD and pharmacotherapy to 
improve quality of life
Cardiovascular disease This chapter focuses on recommendations to determine the absolute risk for cardiovascular disease 
(CVD) based on multiple risk factor assessment for people without an established diagnosis of 
cardiovascular disease. Framingham, non-Framingham risk factors and clinically high risk conditions 
are presented as well as recommendations for chemoprophylaxis. Recommendations for those with 
an established diagnosis of CVD are also presented. The Australian cardiovascular risk charts are 
given in Appendix 1
Chronic kidney disease New recommendations include screening for chronic kidney disease (CKD) risk factors for those 
without risk, screening for CKD with eGFR and urinary albumin-creatinine ratio for those with a 
risk factor, and supporting population-based strategies to reduce scabies and pyoderma among 
children. Numerous behavioural and chemoprophylaxis recommendations have also been included
Diabetes prevention New recommendations include screening for diabetes from >18 years of age in regions with high 
diabetes prevalence and/or with high risk conditions, but consider an AUSDRISK assessment 
only in populations with low prevalence. Behavioural recommendations focus on diet, physical 
activity and breastfeeding. Pharmacotherapy is discussed for people with a high risk condition and 
advocacy for community based interventions are recommended
Cancer Focuses on five areas for prevention and early detection of cancer: cervical, breast, liver, prostate 
and bowel cancer. Liver, prostate and bowel cancer are new topics
New recommendations for cervical cancer include promoting human papilloma virus (HPV) 
vaccination and commencing Pap screening regardless of HPV vaccination status. Other 
recommendations include assessing smoking status and offering a sexual health review
New recommendations for breast cancer include discussing familial breast cancer and breast 
awareness, while mammographic screening differs depending on age and level of risk. New 
behavioural recommendations cover physical activity, diet, alcohol consumption, smoking and 
breastfeeding. Hormone replacement therapy and other pharmacotherapy are discussed






Who is at 
risk?
What should be done? How often? Level/
strength of 
evidence
Screening People aged 
≥10 years
Smoking status should be assessed for every patient 
over 10 years of age on a regular basis 
Opportunistic 
and as part of 





A system for identifying all smokers and documenting 
tobacco use should be used in every health service 




Assess the level of nicotine dependence to help 
predict relapse to smoking and guide intervention 
choice (eg. Fagerström test: see Resources)
Opportunistic GPP
Behavioural Non-smokers Advise non-smokers to limit their exposure to tobacco 
smoke, especially parents of babies, young children 
and pregnant women
Parents who smoke should be counselled not to 
smoke in the house or in a confined space such as a 
motor vehicle
Opportunistic IIIC
Recommendations: Interventions for smokers
Preventive 
intervention type
Who is at 
risk?





All patients who smoke, regardless of the amount they 
smoke and whether they express a desire to smoke or 
not, should be offered brief cessation advice at every 
visit (consider using the 5As framework – see Chapter 
1: Lifestyle, introduction)
Opportunistic at 
every visit and 




Brief interventions should be adapted to local cultural 
setting (see Resources: SmokeCheck)  
N/A GPP
Smoking cessation counselling should be offered to 
all people at every opportunity, and if possible, should 
comprise at least four face-to-face or group support 
sessions
Opportunistic IA
Consider referral to a proactive smoking cessation 
telephone service such as a quitline, particularly for 
people with limited access to face-to-face counselling 
Opportunistic  IIA
Make available tailored self help quit smoking materials, 







Offer follow up visits for smokers attempting to quit Within 1 week of 
quitting
Then within 
1 month of 
abstinence 
Then opportunistic 







Offer intensive smoking cessation counselling 
(see Chapter 9: Antenatal care, for detailed 
recommendations)
IA–IIIC
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Chemoprophylaxis Current 
smokers
Recommend smoking cessation pharmacotherapies to 
patients interested in quitting. First line treatments are 
NRT, bupropion and varenicline
Pregnant women may be offered NRT if the benefits 
outweigh the risks (see Chapter 9: Antenatal care)
Opportunistic IA
GPP
Environmental Complement the above individual based strategies with 
a community based approach to tobacco control (eg. 
promotion of smoke free workplaces)
IIIC
Promote training of Aboriginal and Torres Strait Islander 
health workers in brief interventions for smoking 
cessation to increase quit rates
N/A GPP
Table 1.1. The 5As model for behavioural and other interventions 
related to lifestyle risk factors
Assess 
Ask about/assess behavioural health risk(s) and factors affecting choice of behaviour change 
goals/methods 
Advise 
Give clear, specific, and personalised behaviour change advice, including information about 
personal health harms and benefits. It recognises that the health practitioner can be a catalyst 
for action and can enhance motivation for change
Agree*
Collaboratively select appropriate treatment goals and methods based on the patient’s interest 
in and willingness to change the behaviour. This involves joint consideration of treatment 
options, consequences and patient preferences and setting management goals 
Assist
Using behaviour change techniques (self help and/or counselling), aid the patient in achieving 
agreed upon goals by acquiring the skills, confidence and social/environmental supports for 
behaviour change, supplemented with adjunctive medical treatments when appropriate (eg. 
pharmacotherapy for tobacco dependence)
Arrange 
Schedule follow up contacts (in person or by telephone) to provide ongoing assistance/support 
and to adjust the treatment plan as needed, including referral to more intensive or specialised 
treatment. Follow up visits often involve repeating the preceding 4As







Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people aged 
<18 years
Assess BMI using age and sex specific centile 
charts (see Chapter 2: Child health and 
Resources)
Opportunistic 
and as part of 
an annual health 
assessment 
GPP
All people aged 
≥18 years
Assess BMI and waist circumference (see Table 
1.2)
Opportunistic 
and as part of 
an annual health 
assessment 
GPP
Groups associated with improved outcomes 
from BMI/waist circumference monitoring 
include:
•	 individuals seeking advice on weight 
management
•	 those with conditions associated with 
overweight/ obesity (CVD, diabetes, stroke, 
gout, liver or gallbladder disease)
1B
Behavioural All people aged 
≥18 years
Provide brief advice to promote healthy eating 
and physical activity as per Australian guidelines 





Develop a weight management plan that must 
include:
•	 targeted information as per Australian dietary 
guidelines (see Table 1.3)
•	 goal setting
•	 at least one follow up consultation
Opportunistic 
and as part of 
an annual health 
assessment
 IB
Encourage regular self weighing IC
Encourage a net energy deficit through 
combined dietary and physical activity 
interventions as per Australian dietary and 
physical activity guidelines
IB
Consider referral to specialist services, dietitian 
and/or exercise physiologist if available
GPP
Individual or group based psychological 
interventions* are recommended in combination 





Develop a targeted weight management plan 
as for adults. This plan must involve at least 
one parent/carer and aim to change the whole 
family’s lifestyle
Opportunistic 
and as part of 
an annual health 
assessment
IB
Except in severe obesity, weight maintenance 
rather than weight loss is recommended for 
healthy growth and development
Recommend referral for specialist review for 
children with severe obesity
IVD
Chemoprophylaxis People aged 
≥18 years with 






arthritis, type 2 
diabetes) and a 
BMI ≥28 kg/m2
Assess risk/benefit of orlistat on an individual 
basis in conjunction with lifestyle interventions
Opportunistic 
and as part of 
an annual health 
assessment
IA
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Surgical People aged 
≥18 years with 




above) and a 
BMI ≥35 kg/m2
Assess risk/benefit of bariatric surgery on an 
individual basis in conjunction with lifestyle 
interventions 
Opportunistic IIC
Environmental Communities Advocate for multifactorial and coordinated 
community based interventions to increase 
access to healthy and nutritious food (eg. 
subsidised healthy food in stores)
N/A GPP
*  Cognitive focused behavioural interventions include: situational control and stimulus control, avoiding cues to overeating,  
cognitive reframing and reinforcement techniques, self recording of calorie intake and eating behaviours, goal setting and relapse 
prevention strategies
Table 1.2. Combining measures to assess obesity and disease risk* in adults
Classification Body mass index  
(kg/m2) 
Disease risk (relative to normal measures)
Waist circumference
Men 94–102 cm 
Women 80–88 cm 
Waist circumference
Men >102 cm 
Women >88 cm
Underweight <18.5 – –
Healthy weight 18.5–24.9 – Increased
Overweight 25.0–29.9 Increased High
Obesity 30.0–39.9 High to very high Very high
Severe obesity >40 Extremely high Extremely high
* Risk of type 2 diabetes, elevated blood pressure and cardiovascular disease
Source: NHMRC 2003a2
Table 1.3. Dietary guidelines for Australian adults*
•	 Enjoy a wide variety of nutritious foods
•	 Eat plenty of vegetables, legumes and fruits
•	 Eat plenty of cereals (including breads, rice, pasta and noodles), preferably wholegrain
•	 Include lean meat, fish, poultry and/or alternatives
•	 Include milks, yoghurts, cheeses and/or alternatives. Reduced-fat varieties should be chosen, where 
possible
•	Drink plenty of water
•	Choose store foods that are most like traditional bush foods*
•	 Enjoy traditional bush foods whenever possible*
•	 And take care to:
 –  limit saturated fat and moderate total fat intake
 –  choose foods low in salt
 –  limit your alcohol intake if you choose to drink
 –  consume only moderate amounts of sugars and foods containing added sugars
Source: NHMRC 2003b28
* Recommendations specific to some Aboriginal and Torres Strait Islander communities








Who is at 
risk?
What should be done? How often? Level/
strength of 
evidence
Screening All people Assess current level of physical activity Opportunistic 
and as part of 
an annual health 
assessment
IB
Behavioural All people For patients who are insufficiently active give targeted 
advice and written information. This should include the 
following:
•	 determine existing preferred physical activities and 
invite patients to propose new activities
•	 ask the patient the amount/frequency of activity 
they feel is achievable and set exercise goals aiming 
to achieve National Physical Activity Guideline 
recommendations (see Table 1.4)
•	 record these goals and provide patients with a written 
copy
•	 consider cognitive behavioural support and follow up
•	 consider additional social support (eg. buddy system, 
involvement in a group activity, referral for coaching)
People with 
diabetes
For sedentary people, a gradual introduction and initial 
low intensity of physical activity with slow progressions in 
volume and intensity is recommended 
Those on insulin should be given individualised advice on 
avoiding hypoglycaemia when exercising (eg. adjustment 
of carbohydrate intake, reduction of insulin dose, and 
choice of injection site)
Consider referral to an exercise physiologist for coaching 
if facilities are available
Opportunistic 
and as a part 







Those with recent acute coronary syndrome event or 
revascularisation surgery (CABG, PCI) should be advised 
to participate in a short period (up to 12 weeks) of 
supervised exercise rehabilitation
Opportunistic  IA
Those who are well compensated and clinically stable 
should commence an initial low intensity of physical 
activity with slow progressions in volume and intensity
Consider referral to an exercise physiologist for coaching 
if facilities are available
IIB
Environmental All people Refer to appropriate community based physical activity 
programs and encourage use of public facilities that 
promote activity (eg. advocate for increased availability of 
sports and recreational facilities in remote communities)
Opportunistic 
and as part of 
an annual health 
assessment
IB
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Table 1.4. Australian physical activity guidelines: 
Recommendations by age group 
Age group Recommendation
Under 2 years For children under 1 year supervised floor based play in safe 
environments should be encouraged from birth
For children under 2 years no time watching television or using other 
electronic media
2–5 years Toddlers and preschoolers should be physically active every day for at 
least 3 hours, spread throughout the day
Watching television and the use of other electronic media (DVDs, 
computer and other electronic games) should be limited to less than 1 
hour per day
5–12 years At least 60 minutes (and up to several hours) of moderate to vigorous 
physical activity every day
No more than 2 hours per day using electronic media for entertainment 
(eg. computer games, TV, internet), particularly during daylight hours
12–18 years At least 60 minutes of moderate to vigorous physical activity every day
No more than 2 hours per day using electronic media for entertainment 
(eg. computer games, TV, internet)
18–54 years The following 4 steps are recommended:
•	 Think of movement as an opportunity, not an inconvenience
•	Be active every day in as many ways as you can
•	 Put together at least 30 minutes of moderate physical activity on most, 
preferably all days. 30 minutes can be accumulated throughout the day 
in 10–15 minute sessions or done in one session
•	 If you can, also enjoy some regular vigorous activity for extra health and 
fitness
55 years and over Older people should do some form of physical activity, no matter what 
their age, weight, health problems or abilities
Older people should be active every day in as many ways as possible, 
doing a range of physical activities that incorporate fitness, strength, 
balance and flexibility
Older people should accumulate at least 30 minutes of moderate physical 
activity on most, preferably all days. Sedentary people may need to 
gradually build up to 30 minutes or more
Older people who have stopped physical activity, or who are starting a 
new physical activity, should start at a level that is easily manageable 
and gradually build up the recommended amount, type and frequency of 
activity
Older people who continue to enjoy a lifetime of vigorous physical activity 
should carry on doing so in a manner suited to their capability into 
later life, provided recommended safety procedures and guidelines are 
adhered to
Source: Department of Health and Ageing 201092








Who is at 
risk?
What should be done? How often? Level/
strength of 
evidence
Screening All people 
aged ≥15 years
Ask about the quantity and frequency of alcohol 
consumption to detect hazardous drinkers (see Table 
1.5) 




Focus particularly on the following high risk groups:
•	 adolescents and young adults 
•	women who are pregnant or planning a pregnancy
•	 illicit drug users
•	 those with a family history of alcohol dependence
•	 people with medical conditions made worse by 
alcohol (chronic liver disease, hypertension, other 
major organ disease)
•	 people suffering from mental illness made worse by 
alcohol such as anxiety and depression
Opportunistic I–IIIB
Consider the use of structured questionnaires such 
as AUDIT, AUDIT-C or IRIS to assess drinking (see 
Resources – these tools may require some adaptation 
to local community needs)






Consider sensitive and age appropriate alcohol intake 
screening in aged 10–14 years (see Chapter 3: The 
health of young people)
Parental or carer involvement may be required and 
referral should be considered








Review for comorbid disease and other chronic 
disease risk factors








Offer brief interventions. Consider using tools such as 
FLAGS and 5As approach (see Table 1.1 and 1.6 and 
Chapter 1: Lifestyle, introduction) 
Brief interventions alone are not sufficient for people 
with severe alcohol related problems or alcohol 
dependence who require referral or extended 
intervention. (Treatment specific guidelines should be 
consulted in these circumstances)
Opportunistic 
and as part of 









Advise to abstain from alcohol, emphasising the risks 
to the unborn child
Advise breastfeeding mothers that not drinking is the 
safest option, especially in the first month postpartum. 
For those choosing to drink, alcohol intake should be 
limited to no more than two standard drinks per day. 
Continue to promote  
breastfeeding
Pregnant women: 
At first and 
subsequent 
antenatal visits as 
appropriate
For all others 
opportunistic 
and as part of 
an annual health 
assessment
IA
Environmental Promote community led strategies to reduce alcohol 
supply including:
•	 advocacy for ‘dry communities’
•	 restrictions to liquor licensing hours
•	 better policing of responsible service of alcohol
•	 community development initiatives
GPP
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Table 1.5. National Health and Medical Research Council guidelines for 
safer alcohol use
For healthy men and women, drinking no more than two standard drinks on any day reduces the 
lifetime risk of harm from alcohol related disease or injury
For healthy men and women, drinking no more than four standard drinks on a single occasion reduces 
the risk of alcohol related injury arising from that occasion 
For children and young people under 18 years of age, not drinking alcohol is the safest option: 
•	  parents and carers should be advised that children under 15 years of age are at the greatest risk of 
harm from drinking and that for this age group, not drinking alcohol is especially important
•	  for young people aged 15−17 years, the safest option is to delay the initiation of drinking for as long 
as possible
Maternal alcohol consumption can harm the developing fetus or breastfed baby: 
•	 for women who are pregnant or planning a pregnancy, not drinking is the safest option
•	 for women who are breastfeeding, not drinking is the safest option
Source: NHMRC 200993
Table 1.6. The FLAGS framework for brief intervention 
Feedback •	 Provide individualised feedback about the risks associated with continued drinking, 
based on current drinking patterns, problem indicators, and health status
•	 Discuss the potential health problems that can arise from risky alcohol use
Listen •	 Listen to the patient’s response
•	 This should spark a discussion of the patient’s consumption level and how it relates to 
general population consumption and any false beliefs held by the patient
Advice •	 Give clear advice about the importance of changing current drinking patterns and a 
recommended level of consumption
•	 A typical 5–10 minute brief intervention should involve advice on reducing consumption 
in a persuasive but non judgemental way
•	 Advice can be supported by self help materials, which provide information about the 
potential harms of risky alcohol consumption and can provide additional motivation to 
change
Goals •	 Discuss the safe drinking limits and assist the patient to set specific goals for changing 
patterns of consumption
•	 Instil optimism in the patient that his or her chosen goals can be achieved
•	 It is in this step, in particular, that motivation-enhancing techniques are used to 
encourage patients to develop, implement and commit to plans to stop drinking
Strategies •	 Ask the patient to suggest some strategies for achieving these goals
•	 This approach emphasises the individual’s choice to reduce drinking patterns and allow 
them to choose the approach best suited to their own situation
•	 The individual might consider setting a specific limit on alcohol consumption, learning to 
recognise the antecedents of drinking, and developing skills to avoid drinking in high risk 
situations, pacing one’s drinking and learning to cope with everyday problems that lead 
to drinking
Source: Haber P, Lintzeris N, Proude E, Lopatko O 200997







Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people aged >12 
years
Consider asking patients if they participate in 
gambling activities (eg. ‘pokies’, cards, roulette, 
blackjack and other table gambling, lotteries, 
sport associated gambling)
For those who are gambling, screen for problems 
by asking a simple question such as: ‘Have you 
ever had an issue with your gambling?’ 
Specific groups at risk of problem gambling 
include people with stress related medical 








Young people aged 
12–24 years
Consider screening young people for gambling 
behaviours as part of general screening tools 
such as HEEADSSS (see Chapter 3: The health 
of young people)
GPP
High risk groups 
such as young 
people or adults 
with mental health 
or substance use 
problems
Consider use of a validated measurement tool for 





who are known 
to have problem 
gambling
Assess the impact of family gambling on children Opportunistic GPP
Behavioural All people identified 
with problem 
gambling
Management options for problem gambling 
include:
•	 brief treatments and motivational interviewing 
aimed at promoting behaviour change
•	 cognitive behavioural therapy 
•	 treatment of coexistent and complicating 
factors such as depression and substance 
abuse
•	 referral to gambling support helplines and 
websites (see Resources)
•	 referral to gambling treatment centres
Opportunistic GPP
Environmental Young people aged 
from 12 years
Where appropriate, engage with local school 
authorities and support implementation of school 
based gambling prevention strategies
Encourage teachers, parents and healthcare 
professionals to be more aware of adolescent 
gambling
N/A IIIB
Communities Adopt or support community focused activities 
(eg. community campaigns) that promote 
strategies to control gambling and related harms
N/A GPP
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Who is at 
risk?
What should be done? How often? Level/ 
strength of 
evidence
Immunisation* All children Conduct regular postnatal review of all infants and 
offer vaccination










Implement provider/system based interventions: 
review vaccination status at each clinic visit and make 
a documented plan for the next vaccination
Every visit IA
Ascertain local clinic vaccination rates via audits of 
health records and Australian Childhood Immunisation 
Register records
N/A IA
Implement recall and reminder systems and computer 
prompts for staff and patients to address immunisation 
gaps, particularly in the first 12 months
N/A IA
Implement an adverse events reporting system N/A IA
Increase access to vaccinations via: 
•	 fast tracking children presenting for immunisation 
•	 training and reminders for staff to screen and offer 
vaccinations
•	 providing home visits and mobile clinics for 
immunisation
If resources are limited, focus particularly on 
vaccinations due in the first 12 months
N/A IA
Increase community demand for vaccinations by:
•	 promoting vaccination to parents, child care staff, 
and community workers such as Aboriginal and 
Torres Strait Islander liaison officers
•	 using posters and other visual materials in public 
places 
•	 personalising health records
•	 giving all parents/carers a record in card or book 
form of their child’s immunisation status
•	 commencing promotional activities for parents of 
neonates early and in places where parents of very 
young babies attend
Ongoing IA
*  Vaccination should be implemented according to best practice recommendations in the Australian Immunisation Handbook and state 
and territory immunisation schedules
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All children aged >6 months 
from communities with 
a high prevalence of iron 
deficiency anaemia (IDA)
Children in other areas with 
risk factors:
•	 history of low birthweight 
or pre-term birth 
•	maternal anaemia
•	 twin
•	 failure to thrive
•	 chronic infections
Take a nutritional history asking about intake of 
iron rich foods such as meat and fortified cereals, 
leafy green vegetables and vitamin C intake with 
meals
At age 6–9 
months and 
repeat at 18 
months
GPP
Perform haemoglobin (Hb) via point-of-care 
capillary sample or venous blood (including blood 
film)*†
Test at age 
6–9 months 




testing if IDA is 
diagnosed
IIC
Behavioural Babies born without risk 
factors for IDA (see below)
Recommend exclusive breastfeeding to 6 months Opportunistic IB
Babies born with low 
birthweight (<2500 g), 
prematurity (<37 weeks) or to 
mothers who had maternal 
anaemia
Recommend exclusive breastfeeding to 4 months GPP
All babies Introduce iron rich foods at weaning. Examples 
include meat (three serves per week), fortified 
cereals, leafy green vegetable, eaten with vitamin 
C rich food (eg. fresh citrus fruit)
Also discuss withholding cow’s milk until 12 
months of age and avoiding tea
IB
Chemoprophylaxis Babies aged <6 months with 
IDA risk factors as above
Consider oral iron supplementation in consultation 
with a paediatrician
GPP
Children aged 6 months to 
16 years in areas with high 
rates of hookworm infections
Consider use of single dose albendazole as part 
of a systematic child health surveillance program 
in consultation with local public health units





Environmental Children with IDA Include children on recall registers for regular 
review and Hb repeat testing as per above
N/A GPP
Communities with a known 
high prevalence of IDA
Advocate for and support nutritional programs 
that remove financial barriers to improved 
nutrition and improve the range and accessibility 
of healthy foods alongside the food strategies 





*   Diagnose IDA using erythrocyte indices (eg. blood film, mean cell volume) and Hb levels of less than 110 g/L in children over 6 months of age. 
Consult local laboratories for reference limits of Hb levels in children >2 years
†  There are jurisdictional differences in the screening for anaemia (eg. Queensland and the Northern Territory) and local guidelines should be 
consulted





Who is at 
risk?
What should be done? How often? Level/
strength of 
evidence
Screening All children Recommend growth monitoring (including weight, 
length, head circumference, nutritional and 
psychosocial assessment to coincide with child 
health visits for immunisation* (see Table 2.1) 
At 2, 4, 6, 12, 18, 
24 and 36 months 
and between 4 and 
5 years 
Monitor weight 
more frequently if 
there are concerns
IA
Behavioural All children Discuss growth monitoring findings with the 
family, explaining how weight gains are linked 
to good health and always link the discussion 
with any nutritional intervention currently being 
undertaken
Opportunistic IA
Assess developmental milestones (gross 
motor, fine motor, speech and language, social 
interactions) with growth monitoring checks
Consider using parent report questionnaires and 
questions in patient held record (see Chapter 7: 
Table 7.1)
Maintain a high index of suspicion in children 
with following risk factors: possible fetal alcohol 
syndrome, microcephaly, convulsions and 
prematurity
At 2, 4, 6, 12, 18, 
24 and 36 months, 
and between 4 and 
5 years
IA
Mothers Promote breastfeeding by discussing the health 
benefits, use of peer support, face-to-face health 
professional and postnatal home visits
Opportunistic IB
All families Provide nutrition education counselling targeting 
both families and community workers
Opportunistic IB
Counselling should focus on behaviour change, 
be community driven and integrated with other 
preventive child health programs










Provide home visiting support by referral to an 
early intervention program
Opportunistic IA
Ensure regular communication between primary 
healthcare staff and other agencies so that 
nutritional support programs are integrated with 
psychosocial support
GPP
Chemoprophylaxis Children living 




Recommend anti-helminth treatment with a single 
dose of albendazole
Refer to Australian Therapeutic Guidelines for 
dosing regimen64
Opportunistic IA
Environmental Community food supplementation programs may 
be used short term to overcome issues of lack 
of food security, providing they have the support 
of the community and are part of a multifaceted 
intervention
N/A IA
*  Correction for prematurity must be made until 18 months for head circumference, 2 years for weight and 40 months for height. Measure 
length if <2 years and height if >2 years. Measure head circumference until 36 months of age and body mass index (BMI) from 2 years of 
age. Be sure equipment is calibrated and measurements are accurately done78
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Table 2.1. Conducting a growth monitoring action plan
•	Document carer concerns and the barriers they perceive to breastfeeding and healthy 
nutrition
•	 Explore issues of finances, transport, home storage (refrigerator) availability, numbers 
of people living at home, food preferences, food preparation equipment availability, 
facilities to maintain hygiene and hygiene practices
•	 Involve the carer in finding solutions to problems, and focus on finding solutions that 
are practical and context specific, paying particular attention to family needs and 
resources 
•	Give information about appropriate weaning foods and amounts 
•	Consider linking the child to a team approach involving an Aboriginal and Torres Strait 
Islander health worker, community nurse, family support worker and dietitian if there 
are indications that the child is at risk of FTT or showing early signs of growth faltering 
•	Document review dates and begin next review by review of previous action plan
21National guide to a preventive health assessment for Aboriginal and Torres Strait Islander peopleChild health
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All children without a 
high risk condition
Routine urinalysis or blood pressure screening for 
kidney disease is not recommended unless there 
is a clinical indication
N/A IA
Children living in 
areas with high rates 
of infectious skin 
disease (scabies and 
impetigo)
Check the skin for scabies and impetigo and 
treat according to management guidelines
Opportunistic 
and as 




Children with first 
episode UTI
Assess need for imaging tests based on 
treatment response within 48 hours and whether 






Check albumin to creatinine ratio (ACR) using 
single voided specimen, morning specimen 
preferred
5 years after 
diagnosis or at 
age 11 years, 






Behavioural Children who have 
had at least one 
episode of UTI
Identify and correct predisposing factors for 
recurrence (including constipation, dysfunctional 





Children living in 
areas with high rates 
of infectious skin 
disease (scabies and 
impetigo)
Treat household contacts of someone with 
scabies with 5% permethrin cream if over 2 
months old and sulphur 5% or crotamiton cream 
if <2 months of age 
In communities where there are outbreaks of 
infected scabies, offer all household contacts of 
people with impetigo a single dose of benzathine 
penicillin G (see Resources)
As needed IIIC
Environmental Children living in 
areas with high 
rates infectious skin 
disease (scabies and 
impetigo)
Promote good hygiene practices at home
Refer to relevant housing support services to 
promote access to adequate washing facilities 
and toilets
Opportunistic IA
Community based interventions that use 
screening and immediate treatment for skin sores 
and scabies in targeted age groups should be 
combined with simultaneous treatment of the 
whole community for scabies (see Resources)
N/A IA
22
Table 2.2. Recommended imaging following first 
presentation with UTI
Infants younger than 6 months




Ultrasound during the acute infection No Yes
Ultrasound within 6 weeks Yes No




Children aged 6 months to 3 years




Ultrasound during the acute infection No Yes
Ultrasound within 6 weeks No No




Children aged 3 years or more




Ultrasound during the acute infection No Yes
Ultrasound within 6 weeks No No




DMSA = dimercaptosuccinic acid scan (an intravenous radionuclide scan for assessing renal 
function), MCUG = micturating cystourethrogram
*  Atypical UTI features include: the patient is seriously ill, poor urine flow, abdominal or bladder 
mass, raised creatinine, septicaemia, failure to respond to treatment with suitable antibiotics 
within 48 hours, infection with non-E. coli organisms
†  MCUG should not be performed routinely but should be considered if any of the following 
features are present: dilatation on ultrasound, poor urine flow, non-E. coli infection, family 
history of VUR
Source: National Collaborating Centre for Women’s and Children’s Health, 2007.127 Refer to this 
resource for imaging recommendations for recurrent UTI
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
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Who is at risk? What should be done? How often? Level/strength 
of evidence
Screening All young people 
aged 12–24 years
Conduct a psychosocial assessment to 
obtain a holistic assessment of health and to 
determine risk factors affecting wellbeing
Useful tools include the HEEADSSS 
assessment (see Appendix 3.2)
Opportunistic 
and as part of 







Who is at risk? What should be done? How often? Level/strength 
of evidence
Screening All young people 
aged 12–24 years
Ask if sexually active and identify at risk 
sexual behaviours (eg. unprotected sexual 
intercourse: see Chapter 8: Table 8.1)
Opportunistic 
and as part of 






Behavioural All young people Provide anticipatory guidance* and sexual 
health education, tailoring the information 
according to whether a young person is 
sexually active or not (see Chapter 8: Sexual 
health and bloodborne viruses)
Discussion should include the following:
•	 sexual development and sexual feelings
•	 prevention of unplanned pregnancies 
including abstinence
•	 resisting sexual and peer pressure
•	methods of reversible contraception, 
access to and use of emergency 
contraception
Opportunistic 
and as part of 







activity or who are 
sexually active
Recommend use of and/or provide condoms 
Discuss the proper methods for condom 
usage
Opportunistic 
and as part of 




engaging in risky 
sexual behaviour
Use individual behaviour change techniques 
such as brief interventions (eg. information 
giving, motivational interviewing) and 
cognitive behavioural therapy
Opportunistic GPP
Offer or refer to theory based pregnancy 
prevention/education programs to improve 
knowledge and increase contraceptive use. 
Examples include social cognitive theory,† 
motivational interviewing program, AIDS risk 
reduction model (see Table 3.1)
IA
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Provide health guidance to parents and 
other guardians regarding youth sexual 
health following the principles of anticipatory 
guidance*
At least once at 
early, middle and 
late adolescence
GPP






Assess suitability for and offer hormonal 
contraception. Methods include the oral 
contraceptive pill and long acting reversible 
contraception (ie. progestogen only 
injections, progestogen only subdermal 
implants, progestogen only IUDs)
Opportunistic IIIC
Young females 
who have had 
unprotected 
intercourse
Conduct a detailed history to assess the 
context
Discuss and recommend emergency 
contraception as necessary
Arrange for appropriate follow up
Opportunistic IIB
Environmental N/A Promote youth friendly primary healthcare 
services
N/A GPP
*  Anticipatory guidance is a developmentally based counselling technique that focuses on a young person’s stage of development. 
Counselling is focused towards gaining a better understanding of young people’s physical growth, psychosocial and psychosexual 
development. It emphasises the importance of the young person becoming actively involved in decisions regarding their healthcare11
† Social cognitive theory is a learning theory based on the idea that people learn by watching what others do and do not do
Table 3.1. The AIDS risk reduction model
This model has three stages and is based on several other behaviour change 
theories, including the health belief model, ‘efficacy’ theory, emotional influences and 
interpersonal processes. The three stages outlined below are behaviour labelling, 
commitment to change and taking action 
Stage Influences 
1.  Recognition and labelling of one’s 
behaviour as high risk 
•	Knowledge of sexual activities associated with 
HIV transmission
•	Believing that one is personally susceptible to 
contracting HIV 
•	Believing that having AIDS is undesirable
•	 Social norms and networking
2.  Making a commitment to reduce 
high risk sexual contacts and to 
increase low risk activities 
•	Cost and benefits 
•	 Enjoyment (eg. will the changes affect my 
enjoyment of sex?)
•	Response efficacy (eg. will the changes 
successfully reduce my risk of HIV infection?) 
•	 Self efficacy 
•	Knowledge of the health utility and enjoyability 
of a sexual practice, as well as social factors 
(group norms and social support), are 
believed to influence an individual’s cost and 





Depending on the individual, phases 
may occur concurrently or phases 
may be skipped
•	 Social networks and problem solving choices 
(self help, informal and formal help)
•	 Prior experiences with problems and solutions 
•	 Level of self esteem 
•	Resource requirements of acquiring help
•	 Ability to communicate verbally with sexual 
partner 
•	 Sexual partner’s beliefs and behaviours
Source: Family Health International 200239
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Immunisation All young people 
aged 12–24 years
Review hepatitis B immunisation and immune status 
and offer vaccination where indicated (see Chapter 
8: Sexual health and bloodborne viruses)





Screening All young people Assess for presence of risk factors for illicit drug use 
(see Table 3.2)





with risk factors 
for drug use (see 
Table 3.2)
Administer one of the following questionnaires to 
ascertain drug use:
•	 CRAFFT screening tool (≤21 years)
•	 IRIS tool (≥18 years)
•	 Substances and Choice scale (13–18 years (see 
Resources)
Opportunistic IIIB
Behavioural Young people 
with multiple risk 
factors for drug 
use (see Table 3.2)
Refer for preventive case management where 
services are available*
Opportunistic IB
Young people who 
are using illicit 
drugs
Provide brief interventions (eg. in conjunction 
with administration of one of the above screening 
questionnaires). (See also the 5As framework 
Chapter 1: Lifestyle, introduction)
Opportunistic IIIB
Refer to drug education programs based on social 
learning theories (eg. life skills program, peer 
education, youth sport/recreation program)
Opportunistic IIB
Families of young 
people who are 
using illicit drugs
Consider referral where appropriate to parent 
education programs and family intervention therapy 
to encourage healthy family development and 
reduction of parent-adolescent conflict 
Opportunistic IIB
Young people who 
are using injecting 
drugs
Refer to needle and syringe exchange programs 
where appropriate
Opportunistic IB
Environmental N/A Promote school completion N/A GPP
Promote access to community and school based 
drug education programs (based on social learning 
theories)
IB
Promote youth friendly, primary healthcare services
Support increased access to youth workers
GPP
Support community driven illicit drug use prevention 
programs (especially valuable for inhalant abuse)
IIB
Support and promote community engagement 
strategies such as mentorship
IB
Support supervised injecting centres IIB
*  Preventive case management involves the coordinated delivery of intensive services tailored to meet a range of developmental needs. 
It requires intensive case management through coordinating family intervention, after school activity, mentoring, tutoring, individual 
psychiatric assessment and counseling. The approach therefore will involve complex coordination across a range of service types such 
as health, juvenile justice, education, and substance abuse. Key aspects are to assess needs, identify relevant services, coordinate 
service delivery and monitor outcomes. The young person (and if possible the family) should be involved in developing the service 
delivery objectives.44 This can be similar to developing a care plan for people with chronic conditions
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Table 3.2. Risk factors for illicit drug use
Individual influences
•	Not completing secondary school
•	Unemployment
•	Delinquency
•	Residing in remote and very remote areas
•	 Favourable attitudes to drug use 
•	 Sensation seeking and adventurous personality
•	Relationships with peers involved in drug use




•	 Parental attitudes to drug use and rules around drug use
•	 Alcohol and drug problems in the family
Community influences
•	 Perceived and actual level of community drug use
•	Community disadvantage and disorganisation
•	 Availability of drugs within the community
•	 Positive media portrayal of drug use
Sources: Loxley W, Toumbourou J, Stockwell T, Haines B, Scott K, Godfrey C, et al 2004 and 
Australian Institute of Health and Welfare 200544,53
Appendix 3.1. Stages of adolescent development
Early (10–13 years) Middle (14–17 years) Late (18–21 years)
Central 
question
‘Am I normal?’ ‘Who am I?’
‘Where do I belong?’




•	Coming to terms with 
puberty
•	 Struggle for autonomy 
commences





•	 Experimentation and risk taking
•	Relationships have self centred 
quality
•	Need for peer group acceptance
•	 Emergence of sexual identity
•	 Independence from parents
•	Realistic body image
•	 Acceptance of sexual identity
•	Clear educational and 
vocational goals, own value 
system
•	Developing mutually caring and 
responsible relationships
Main concerns •	 Anxieties about body shape 
and changes
•	Comparison with peers
•	 Tensions between family and 
adolescent over independence
•	Balancing demands of family and 
peers
•	 Prone to fad behaviour and risk 
taking
•	 Strong need for privacy
•	Maintaining ethnic identity while 
striving to fit in with dominant 
culture
•	 Self responsibility
•	 Achieving economic 
independence






•	 Still fairly concrete thinkers
•	 Less able to understand 
subtlety
•	Daydreaming common
•	Difficulty identifying how 
their immediate behaviour 
impacts on the future
•	 Able to think more rationally
•	Concerned about individual 
freedom and rights
•	 Able to accept more responsibility 
for consequences of own behaviour
•	Begins to take on greater 
responsibility within family as part 
of cultural identity
•	 Longer attention span
•	 Ability to think more abstractly
•	More able to synthesise 
information and apply it to 
themselves
•	 Able to think into the future and 
anticipate consequences of 
their actions
Source: Chown P, Kang M, Sanci L, Newnham V, Bennett DL 20081
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Appendix 3.2. HEEADSSS assessment
Assessment area Suggested questions
H – Home Explore home situation, family life, relationships and stability
Where do you live? Who lives at home with you? 
Who is in your family (parents, siblings, extended family)? 
What is your/your family’s cultural background?
What language is spoken at home? Does the family have friends from outside its own cultural 
group/from the same cultural group?
Do you have your own room?
Have there been any recent changes in your family/home recently (eg. moves, departures)?
How do you get along with mum and dad and other members of your family? 
Are there any fights at home? If so, what do you and/or your family argue about the most?
Who are you closest to in your family?
Who could you go to if you needed help with a problem?
E – Education/
Employment
Explore sense of belonging at school/work and relationships with teachers/peers/
workmates, changes in performance 
What do you like/not like about school (work)? What are you good at/not good at? 
How do you get along with teachers/other students/workmates? 
How do you usually perform in different subjects? 
What problems do you experience at school/work?
Some young people experience bullying at school: have you ever had to put up with this?
What are your goals for future education/employment?
Any recent changes in education/employment?
E – Eating/Exercise Explore how they look after themselves, eating and sleeping patterns
What do you usually eat for breakfast/lunch/dinner? 
Sometimes when people are stressed they can overeat, or under eat: do you ever find yourself 
doing either of these?
Have there been any recent changes in your weight? In your dietary habits?
What do you like/not like about your body?
If screening more specifically for eating disorders you may ask about body image, the use of 
laxatives, diuretics, vomiting, excessive exercise, and rigid dietary restrictions to control weight.
What do you do for exercise? 
How much exercise do you get in an average day/week?
A – Activities/peer 
relationships
Explore their social and interpersonal relationships, risk taking behaviour, as well as 
their attitudes about themselves 
What sort of things do you do in your free time out of school/work? 
What do you like to do for fun?
Who are your main friends (at school/out of school)?
Do you have friends from outside your own cultural group/from the same cultural group?
How do you get on with others your own age?
How do you think your friends would describe you?
What are some of the things you like about yourself?
What sort of things do you like to do with your friends? 
How much television do you watch each night?
What’s your favourite music?
Are you involved in sports/hobbies/clubs?
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Appendix 3.2. HEEADSSS assessment (continued)
D – Drug use/
cigarettes/alcohol
Explore the context of substance use (if any) and risk taking behaviours
Many young people at your age are starting to experiment with cigarettes/drugs/alcohol. Have any 
of your friends tried these or other drugs like marijuana, injecting drugs, other substances? 
How about you, have you tried any? If Yes, explore further
How much do you use and how often? 
How do you (and your friends) take/use them? Explore safe/unsafe use, binge drinking, etc.
What effects does drug taking or smoking or alcohol have on you? 
Has your use increased recently? 
What sort of things do you (and your friends) do when you take drugs/drink?
How do you pay for the drugs/alcohol?
Have you had any problems as a result of your alcohol/drug use (with police, school, family, 
friends)?
Do other family members take drugs/drink?
S – Sexuality Explore their knowledge, understanding, experience, sexual orientation and sexual 
practices – look for risk taking behaviour/abuse
Many young people your age become interested in romance and sometimes sexual relationships. 
Have you been in any romantic relationships or been dating anyone?
Have you ever had a sexual relationship with a boy or a girl (or both)? – If Yes, explore further
(If sexually active) What do you use to protect yourself (condoms, contraception)?
What do you know about contraception and protection against STIs?
How do you feel about relationships in general or about your own sexuality? 
(For older adolescents) Do you identify yourself as being heterosexual or gay, lesbian, bisexual, 
transgender or questioning?
Have you ever felt pressured or uncomfortable about having sex?
S – Suicide/Self harm/ 
depression/mood
Explore risk of mental health problems, strategies for coping and available support
Sometimes when people feel really down they feel like hurting, or even killing themselves. Have you 
ever felt that way? 
Have you ever deliberately harmed or injured yourself (cutting, burning or putting yourself in unsafe 
situations eg. unsafe sex)? 
What prevented you from going ahead with it? 
How did you try to harm/kill yourself?
What happened to you after this?
What do you do if you are feeling sad, angry or hurt?
Do you feel sad or down more than usual? How long have you felt that way?
Have you lost interest in things you usually like?
How do you feel in yourself at the moment on a scale of 1 to 10? 
Who can you talk to when you’re feeling down? 
How often do you feel this way? 
How well do you usually sleep? 
It’s normal to feel anxious in certain situations – do you ever feel very anxious, nervous or stressed 
(eg. in social situations)?
Have you ever felt really anxious all of a sudden – for what particular reason? 
Do you worry about your body or your weight? Do you do things to try and manage your weight 
(eg. dieting)? 
Sometimes, especially when feeling really stressed, people can hear or see things that others don’t 
seem to hear or see. Has this ever happened to you? 




Sunscreen protection, immunisation, bullying, abuse, traumatic experiences, risky behaviours
Beliefs, religion, What helps them relax, escape? What gives them a sense of meaning?
Sources: Goldenring J, Rosen D 2004 and Sanci L 200114,76
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Children aged 0–5 years Recommend regular review with a dental 
health professional
Non-dental health professionals are 
encouraged to undertake an oral health 
review including the assessment of teeth, 
gums and oral mucosa as part of a 
regular health assessment (see Table 4.1)
Opportunistic 
and as part of 
an annual health 
assessment
IVC
People aged 6–18 years Annually IVC
Adults with poor oral health 
and/or risk factors for dental 
disease (see Table 4.2) 
People with diabetes, 
immunosuppression, 
haematological conditions, 
bleeding disorders or 
anticoagulant therapy
Annually IVC
All pregnant women At first antenatal 
visit (see Chapter 
9: Antenatal care)
IVC
Adults with good oral health 2 yearly IVC
Those with past history of 
rheumatic heart disease and 
cardiovascular abnormalities
Refer to a dental professional and 
undertake an oral health review as part 
of a regular health assessment (see Table 
4.1) with appropriate oral hygiene advice 
to minimise oral bacterial levels
6–12 monthly IVC
Chemoprophylaxis Children aged 0–5 years Recommend use of fluoride containing 
toothpaste at least once daily, from the 
time the teeth start to erupt
Use a smear of paste for children under 
2 years and a pea-size amount for 
children 2+ years. Toothpaste with a 
fluoride concentration of 1000 ppm is 
recommended unless there is a risk of 
fluorosis 
Opportunistic IA
Children aged 0–5 years 
where families have evidence 
of dental caries, poor oral 
hygiene
Refer to dental professional for regular 
application of fluoride varnish
If resources do not permit then continue 
daily use of fluoride toothpaste and 
provide dietary advice as per Table 4.1
At least every 6 
months from when 
the teeth erupt, 
and for a period 
of not less than 24 
months
IB
People aged >5 years at 
high risk of dental caries (see 
Table 4.2) 




People at high risk of 
endocarditis 
(rheumatic heart disease, 
previous infective 
endocarditis, prosthetic 
cardiac valves, certain forms 
of congenital heart disease, 
cardiac transplantation)
Recommend antibiotic prophylaxis prior 
to dental procedures. See management 
guidelines for specific advice13
Opportunistic GPP
Environmental Communities Advocate for fluoridation of community 
water supply
1A
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Table 4.1. Advice for good oral health practices
While review with dental professionals is recommended to comprehensively assess for caries risk and the presence of disease, 
the following general principles are recommended for non-dental health professionals
Assessment
Visual inspection of teeth for evidence of caries, periodontal disease, assessment of maternal caries and/or poor oral hygiene
Assess oral hygiene practices, consumption of sucrose and sweetened drinks especially in baby bottles, ‘honey on the dummy’ 
or other sweet substances such as glycerine on the dummy, intake of sugared medicines
Assess access to fluoridated water supply
Advice
Brush teeth twice daily with a soft toothbrush and fluoride toothpaste and advise to spit, not rinse, excess paste
Advise about the hazards of high carbohydrate and acidic between meal snacks and drinks
Advise against high and regular consumption of black cola, sweetened fizzy drinks and sports drinks, with water being the 
preferred drink
Promote breastfeeding, with weaning to a baby-cup, not a bottle
If bottles are used, advise against the use of any fluid apart from water and do not put baby to sleep with a bottle
Advise about smoking cessation and limiting alcohol consumption
Use sugar free chewing gum for saliva stimulation
Use a mouth guard when playing contact sport
Recommend regular dental check-up
Source: The RACGP 200927
Table 4.2. Risk factors for dental disease
•	 Poor oral hygiene practices (eg. no/irregular toothbrushing, use of hard toothbrush, no use of fluoride toothpaste, incorrect 
brushing technique)
•	 Poor diet and nutrition (eg. high and regular consumption of sucrose and carbohydrate containing foods and drinks, especially 
black cola, sweetened fizzy drinks)
•	 Salivary composition and flow: if poor then there is less protective effect from saliva
•	 Low exposure to fluoride
•	 Xerostomia or dry mouth can also contribute to development of dental caries. Risk factors for xerostomia include use of 
common medications, particularly antidepressants, antihistamines and antihypertensives; radiotherapy and chemotherapy 
for cancers of the head and neck; Sjögren syndrome; HIV infection; and diabetes, particularly in people with poor glycaemic 
control
•	 High consumption of acidic foods and drinks such as sports drinks and juices can contribute to tooth erosion; bulimia is also 
an erosion risk factor
•	 General risk factors for periodontal disease include smoking, diabetes, advancing age, stress and poor oral hygiene
•	 Tobacco smoking and alcohol consumption are risk factors for the development of oral cancer
•	 HIV infection can also contribute to a greater risk of periodontal disease, oral ulceration and cancer
•	 Other modifying risk factors can include age, socioeconomic status and access to oral health services
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
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Chapter 5: Rheumatic heart disease
Recommendations: Rheumatic heart disease
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people Recommend auscultation of the heart to assess 
for previously undiagnosed RHD
Echocardiography is not currently recommended 
to screen for previously undiagnosed RHD*
Opportunistic 
and as 




All people with 
a past history of 
ARF or murmurs 
suggestive of valve 
disease
Referral for echocardiography and subsequent 
follow up is recommended. See management 





Behavioural People with a past 
history of ARF or 
RHD
Advise that the rate for recurrence of ARF is 50% 
and that there is a need for prophylactic antibiotics 
(see below)
Opportunistic GPP
Recommend dental hygiene, and regular review 
(see Chapter 4: Dental health)
6–12 monthly GPP




common and ARF 
is prevalent
Any sore throat should be treated as if it is a GAS 
pharyngitis infection with a single intramuscular 
benzathine penicillin injection (preferred) or 10 
days of oral penicillin (see specific management 
guidelines18) 
Where possible this should be based on 
confirmation with a throat swab culture
Opportunistic GPP
All people with 
GAS pharyngitis
Treat with 10 days of oral penicillin or a single 
intramuscular benzathine penicillin injection (see 
specific management guidelines18)
There is no need to treat family contacts of those 
with GAS pharyngitis
Opportunistic IA
All people with 
ARF/RHD 
Identify patients for secondary antibiotic 
prophylaxis through inclusion in local recall 
systems and centralised rheumatic fever register 
where one exists
Opportunistic GPP
Categorise patients according to their priority 
status (see Table 5.3) and implement a tailored 
secondary prevention strategy (see management 





Recommend antibiotic prophylaxis for dental 
and other high risk procedures for those with 






common and ARF 
is prevalent
Assess for overcrowding and refer to social 
support services for housing assistance if 
indicated (see Chapter 7: Hearing loss)
If high rates of impetigo and underlying scabies, 
consider community healthy skin program (see 
Chapter 2: Child health)
N/A IIIB
*  Echocardiography is likely to be a superior strategy to auscultation and lead to improved case detection of subclinical RHD. The optimal 
echocardiography based screening strategy, however, is the subject of ongoing research and until the outcomes of this research is 
known routine echocardiography screening is not recommended (see preamble for more details)
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Table 5.1. Australian guideline criteria for acute rheumatic fever
High risk groups* All other groups
Initial episode of 
ARF
Two major or one major and two minor manifestations 
Plus 
Evidence of a preceding GAS infection†
Recurrent 
attack of ARF 
in a patient with 
known past ARF 
or RHD
2 major or 1 major and 1 minor or 3 minor manifestations
Plus 
Evidence of a preceding GAS infection†
Probable ARF 
(first episode or 
recurrence)
A clinical presentation that falls short by either 1 major or 1 minor manifestation, or in 
the absence of streptococcal serology results, but one in which ARF is considered the 
most likely diagnosis. Such cases should be further categorised according to the level of 
confidence with which the diagnosis is made:




Carditis (including evidence of rheumatic 
valvulitis on echocardiogram) 





Carditis (excluding subclinical evidence 










ESR ≥30 mm/hr or CRP  
≥30 mg/L
Prolonged P-R interval on ECG**
Fever ≥38°C¶
Polyarthralgia or aseptic mono-arthritis‡
ESR ≥30 mm/hr or CRP ≥30 mg/L
Prolonged P-R interval on ECG**
ARF = acute rheumatic fever, CRP = C-reactive protein, ECG = electrocardiogram, ESR = erythrocyte sedimentation 
rate, GAS = group A streptococcus infection, RHD = rheumatic heart disease
*   High risk groups are those living in communities with high rates of ARF (incidence >30 per 100 000 per year in 
those aged 5–14 years) or RHD (all-age prevalence >2 per 1000). Aboriginal and Torres Strait Islander people living 
in rural or remote settings are known to be at high risk 
†  Elevated or rising antistreptolysin O or other streptococcal antibody, or a positive throat culture or rapid antigen test 
for GAS
‡  A history of arthritis is sufficient to satisfy this manifestation. Other causes of arthritis/arthralgia should be carefully 
excluded
§  Rheumatic (Sydenham) chorea does not require other manifestations or evidence of preceding GAS infection, 
provided other causes of chorea are excluded
#  Erythema marginatum is a distinctive rash. Care should be taken not to label other rashes, particularly non-specific 
viral exanthemas, as erythema marginatum
¶  Oral, tympanic or rectal temperature ≥38°C on admission or documented during the current illness
**  Note that if carditis is present as a major manifestation, prolonged P-R interval cannot be considered an additional 
minor manifestation in the same person
Source: Rheumatic Heart Disease Australia 20123
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Table 5.2. World Heart Federation criteria for 
echocardiographic diagnosis of rheumatic heart disease
1. Echocardiographic criteria for individuals ≤20 years of age
Definite RHD (either A, B, C or D)
A. Pathological MR* and at least 2 morphological features of RHD of the mitral valve†
B. MS mean gradient ≥4 mmHg (must exclude congenital mitral valve anomalies)
C.  Pathological AR‡ and at least 2 morphological features of RHD of the aortic valve§ 
(must exclude bicuspid aortic valve and dilated aortic root)
D.  Borderline disease of both aortic and mitral valve#
Borderline RHD (either A, B or C) (in high risk populations only)
A.  At least two morphological features of RHD of the mitral valve† without pathological 
MR or MS
B.  Pathological MR*
C.  Pathological AR†
Normal echocardiographic findings (all of A, B, C and D)
A.  MR that does not meet all four Doppler criteria (physiological MR)*
B.  AR that does not meet all four Doppler criteria (physiological AR)‡
C.  An isolated morphological feature of RHD of the mitral valve (eg. valvular thickening), 
without any associated pathological stenosis or regurgitation
D.  Morphological features of RHD of the aortic valve§ (eg. valvular thickening), without 
any associated pathological stenosis or regurgitation 
2. Echocardiographic criteria for individuals >20 years of age
Definite RHD (either A, B, C or D)
A.  Pathological MR* and at least 2 morphological features of RHD of the mitral valve†
B.  MS mean gradient ≥4 mmHg (must exclude congenital mitral valve anomalies)
C.  Pathological AR‡ and at least two morphological features of RHD of the aortic valve§ 
(must exclude bicuspid aortic valve and dilated aortic root)
D.  Pathological AR‡ and at least two morphological features of RHD of the mitral valve†
AR = aortic regurgitation, MR = mitral regurgitation, MS = mitral stenosis, RHD = rheumatic 
heart disease
*   Pathological MR is defined as meeting all four of the following doppler criteria: (A) seen in 2 
views; (B) in at least one view, jet length 2 cm; (C) peak velocity ≥3 m/s; (D) pan-systolic jet in at 
least one envelope
†  Morphological features of RHD in the mitral valve: anterior mitral valve leaflet thickening ≥3 mm 
(age specific), chordal thickening, restricted leaflet motion, excessive leaflet tip motion during 
systole
‡  Pathological aortic regurgitation is defined as meeting all four of the following doppler criteria: 
(A) seen in 2 views; (B) in at least one view, jet length 2 cm; (C) peak velocity ≥3 m/s; (D) pan-
systolic jet in at least one envelope
§  Morphological features of RHD in the aortic valve: irregular or focal thickening, coaptation 
defect, restricted leaflet motion, prolapse
#  Combined AR and MR in high prevalence regions and in the absence of congenital heart 
disease is regarded as rheumatic
Source: Rheumatic Heart Disease Australia 20123
34 National guide to a preventive health assessment for Aboriginal and Torres Strait Islander peopleRheumatic heart disease
Table 5.3. Priority classifications for developing 
management plans
Classification Criteria
Priority 1 (severe) Any of the following:
•	 severe valvular disease
•	moderate/severe valvular lesion with symptoms
•	mechanical prosthetic valves, tissue prosthetic valves and 
valve repairs including balloon valvuloplasty
Priority 2 (moderate) Any moderate valve lesion in the absence of symptoms and 
with normal LV function
Priority 3 (mild) ARF with no evidence of RHD or trivial to mild valvular 
disease
Priority 4 (inactive) Patients with a history of ARF (no RHD) for whom secondary 
prophylaxis has been ceased
Source: Rheumatic Heart Disease Australia 20123
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Infants aged <6 
months
Conduct a general eye examination. Refer 
if red eye reflex absent or other abnormality 
found
As part of a 
newborn and 





Screen for visual acuity (VA) (use E chart if 
required)
Refer if VA is less than 6/9 or there is a two line 
difference between eyes
Opportunistic 
and once only 
at routine health 
assessment
GPP





Near and far visual acuity assessment is 
recommended to detect visual loss due to 
presbyopia or cataract
Annually as part 
of an adult health 
assessment
GPP
The use of near test material and Snellen chart 
(and E chart if required) is recommended for 
testing visual acuity
If unable to see normal sized print (type) 
refer to optometrist or ophthalmologist for 





If visual acuity is worse than 6/12 or when 
function is impaired refer to an ophthalmologist 




Undertake visual acuity and retinal assessment 
by trained assessor as indicated in diabetic 
management guidelines 
 Annually IA
Retinal photography by trained primary 
care staff combined with external review by 
an ophthalmologist is a useful strategy for 
comprehensive screening
GPP
Behavioural Current smokers Advise smoking cessation to reduce the risk of 
developing cataracts (see Chapter 1: Lifestyle, 
section on smoking)
Opportunistic IIIC
All people Recommend reduced ocular exposure to 








Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening People living 
where trachoma 
is endemic (>5% 
prevalence of 
active trachoma in 
young children) 
Implement a community screening program 
in partnership with regional population health 
units to assess the prevalence of active 
trachoma 
No community screening is required where 
prevalence is below 5% of children for 5 
consecutive years









Perform eye examination to ascertain corneal 
scarring and/or the presence of trichiasis 
2 yearly (age 
40–54 years)
Yearly (age 55+ 
years)
GPP
Those with trichiasis,* refer to an 
ophthalmologist for surgery
N/A IIIB
Behavioural All children 
from trachoma 
endemic areas
Recommend to families the importance of 
the following in the prevention and control of 
trachoma:
•	 facial cleanliness of children
•	 effective rubbish disposal and other fly 
control measures
•	 regular screening, and treatment of 
infection
Opportunistic 
and as part of an 
annual child health 
assessment
IIB
Chemoprophylaxis People living 
where trachoma 
is endemic (>5% 
prevalence of 
active trachoma in 
young children)
Treat case and all household contacts using 
community based single dose azithromycin 
(A) on an annual basis
As per state and 
territory protocols
IA 
Environmental All people Assess housing situation for overcrowding 
and refer to social support services for 





Implement joint health promotion strategies 
with state/territory government public health 
units and local shire councils for fly control 






*  Trichiasis is diagnosed when at least one eyelash rubs on the eyeball, or there is evidence of recently removed eyelashes because of 
eyelash in-turning30
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Who is at 
risk?
What should be done? How often? Level/
strength of 
evidence
Immunisation Children aged 
<15 years
Vaccination is recommended to prevent infections that may 
lead to congenital or acquired hearing loss (rubella, measles, 
H. influenzae type b, meningococcus). (See Chapter 2: Child 
health)






Pneumococcal conjugate vaccination (13-valent PCV) is 
recommended during infancy to prevent invasive disease, 
pneumonia and acute otitis media*17
Age 2, 4 and 6 




Annual influenza vaccination (inactivated virus) is 
recommended for any person ≥6 months of age who wishes 
to reduce the likelihood of becoming ill with influenza. 
Vaccination may reduce the incidence of acute otitis media 
as a secondary complication of influenza






Offer testing for rubella immunity and syphilis serology to 
prevent infections which may lead to congenital hearing loss





Ensure parents of newborn infants are aware of the universal 
neonatal hearing screening program being implemented in 
each state/territory and have had their newborn screened for 
congenital hearing impairment 
Prior to age 1 month IC
Children aged 
<15 years
Encourage parents to be aware of child developmental 
milestones in the early detection of hearing loss (see Table 
7.1). Parental suspicion of hearing loss should always be 
investigated (see Table 7.2). Where relevant, provide advice 




and as part of 
an annual health 
assessment 
GPP
Conduct ear examinations (otoscopy) in order to detect 
unrecognised acute or chronic otitis media. If detected, 
refer to clinical practice guidelines for management (see 
Resources) 
Opportunistic and 




<5 years and 
older children 
at high risk 
of hearing 
impairment†
Monitor for hearing loss Opportunistic and 
as part of an annual 
health assessment
GPP
Use the following audiological tools to monitor for hearing 
loss: simplified parental questionnaires (see Table 7.1), and 
pneumatic otoscopy or tympanometry (in children older than 
4 months of age). These methods do not assess hearing
Pneumatic otoscopy or tympanometry is used to identify otitis 
media with effusion (with possible conductive hearing loss). 
Refer to clinical practice guidelines for the identification and 
management of otitis media with effusion (see reference 1 
and 2 and Resources). Those with suspected hearing loss (or 
caregiver concerns) should be referred as shown in Table 7.2
Opportunistic and 





The routine hearing screening of all children upon 
commencement of their first year of compulsory schooling 




Monitor for hearing impairment by questioning, provide 
advice regarding free hearing assessment, and make 
referrals when appropriate
As part of an annual 
health assessment
GPP
All people Inform patients that free hearing assessment (and 
rehabilitation/hearing aids if hearing loss is confirmed) can 
be obtained as part of the Australian Government Hearing 
Services Program and the Community Services Obligation 
(check eligibility criteria‡)
Opportunistic GPP
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Promote exclusive breastfeeding for at least 4 months (and 
preferably to 6 months) to reduce the risk of infants acquiring 
acute otitis media. Refer women to breastfeeding support 




and as part of annual 
health assessment
IB
All smokers Promote smoking cessation and the need to avoid children 
being exposed to cigarette smoke, as passive exposure 
increases the risk of acute, recurrent and chronic otitis 
media. (See Chapter 1: Lifestyle, section on smoking 
cessation) 
Opportunistic and 
as part of an annual 
health assessment
IA
All people Swimming (sea, clean fresh water) should be permitted 
including in children with a prior history of otitis media (all 
forms)
Opportunistic IA
All people A video otoscope may assist in helping patients and 
families to understand ear disease. This may lead to greater 






The use of prophylactic antibiotics in order to prevent the 
onset of acute otitis media is not recommended, except in 
children with recurrent otitis media§
Opportunistic IA
The use of prophylactic antiviral drugs in those with 
confirmed influenza for the purpose of preventing the onset 
of acute otitis media is not recommended 
Opportunistic IA
Environmental Children aged 
<15 years
Assess children at high risk of hearing impairment† with 
regard to their housing situation (ie. if overcrowding is likely, 
functional condition of housing) and refer to social support 
services for housing assistance if indicated (see Table 7.3)61
Annually IIIC
Encourage nose-blowing, facial cleanliness and 
handwashing of children, in order to prevent the transmission 
of infectious disease. Frequent hand washing in child care 
centres can prevent the occurrence of childhood infections 
and episodes of acute otitis media 
Opportunistic IIC
All people Inform families of the danger of loud noise (and for prolonged 
periods), especially for children with a history of ear disease 
(see Resources) 
Opportunistic GPP
*   Aboriginal and Torres Strait Islander children in high risk areas are recommended to also receive 23-valent polysaccharide vaccine (PSV) as a 
booster dose between 18 and 24 months of age as indicated for the prevention of invasive pneumococcal disease. High risk areas include the 
Northern Territory, Queensland, South Australia and Western Australia. This vaccine is not recommended for children in New South Wales, the 
Australian Capital Territory, Victoria or Tasmania18 
†  High risk of hearing impairment: those from socioeconomically deprived communities and from regions with a high prevalence of otitis media
‡   Australian Government Hearing Services Program eligibility (Voucher system) includes all Australian pensioner/sickness allowance recipients 
21 years and older including a dependent of a person in that category.58 For those under 21 years, certain remote area patients, adults with 
complex hearing needs, Aboriginal and Torres Strait Islander persons >50 years of age or Aboriginal participants in CDEP programs of any 
age, the Community Services Obligation component also provides free hearing services59 and can be accessed by the federally funded and 
sole provider of these services: ‘Australian Hearing’.57 The CSO can also be accessed by those aged 21–26 years.60 Private hearing clinics (eg. 
Hearing Life) provide free hearing assessments to anyone 21 years and over 
§   Recurrent otitis media: the occurrence of three or more episodes of acute otitis media in a 6 month period, or occurrence of four or more 
episodes in the past 12 months2
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Table 7.1. Hearing related growth milestones in children
Simplified parental questionnaires can elicit a child’s progress through the following hearing related 
growth milestones:
•	 3–6 months: not communicating by vocalising or eye gaze
•	 9 months: poor feeding or oral coordination
•	 12 months: not babbling
•	 20 months: only pointing or using gestures (ie. not speaking)
•	 24 months: using <20 words, not following simple requests
•	 30 months: no two-word combinations
Source: Darwin Otitis Guideline Group 20102
Table 7. 2. Criteria for referral of children with suspected hearing 
loss, hearing related problems elicited through simplified parental 
questionnaires (Table 7. 1), and/or caregiver concerns
Age of child Refer to
<3 years Major regional hearing centre to determine the level of loss
<5 years and older 
children at high risk of 
hearing impairment*
Paediatrician and audiologist for appropriate developmental assessment and 
hearing tests
<15 years Audiologist or ENT specialist for full hearing assessment
*  High risk of hearing impairment refers to people from socioeconomically deprived communities and from 
regions with a high prevalence of otitis media
Source: Darwin Otitis Guideline Group 20102
Table 7.3. Definition of overcrowded housing circumstances
Households that do not meet the following requirements are deemed to be overcrowded:
•	 There should be no more than two persons per bedroom
•	Children younger than 5 years of age of different sexes may reasonably share a bedroom
•	Children 5 years of age or older of opposite sex should have separate bedrooms
•	Children younger than 18 years of age and the same sex may reasonably share a bedroom
•	 Single household members 18 years or over should have a separate bedroom, as should parents or 
couples
Source: Biddle N 200851
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Chapter 8: Sexual health and bloodborne viruses




Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people with risk 
factors for STIs or 
BBVs (see Table 8.1)
Screen for STIs according to local prevalence 
guidelines and screen for BBVs if risk factors 
are present (see specific recommendations 
below)
Annually and re-
screen 3 months 




Review STI risk factors and screen for other 
STIs according to local prevalence guidelines 
Consider also screening for BBVs if risk factors 
are present (see Table 8.1)
On diagnosis 
and re-screen in 
3 months
GPP
Sexual partners of a 
person with an STI
Ensure contact tracing is undertaken at 
time of diagnosis and appropriate testing 
and treatment is offered to contacts, as per 





Behavioural All sexually active 
people 
Provide sexual health counselling including 
proactive discussion of issues of sexuality
Opportunistic IIB
Recommend condom use with all sexual 
activity
Opportunistic IIIB
People at higher 
risk of HBV or HCV 
infection (see Table 
8.1)
Provide counselling on harm minimisation and 
promote peer education strategies around 
safer sex and injecting drug use
Opportunistic 
and as part of 
an annual health 
assessment
GPP
People with opioid 
dependence
Conduct brief motivational interviewing to 
reduce use of illicit drugs, harm with injecting 
drugs, risky alcohol use and risk of BBV 
infection and STIs, particularly for those 
unlikely to attend specialist treatment (see 
Resources57,58)
Opportunistic IIIC




Assess post-exposure risk using national 
guidelines (see Resources)59 and provide post-
exposure prophylaxis (PEP) within 72 hours of 
the risk exposure when indicated
Refer to local jurisdictions to source PEP 
starter packs and recommendations regarding 
specialist access (see Resources)60
Follow up PEP requires an authorised 
prescriber (under Section 100 Special Access 
Scheme) 
Opportunistic GPP
People with opioid 
dependence
Opioid substitution therapy should be made 
accessible to all populations, including those in 
prison populations and other closed settings





Environmental Injecting drug users Needle and syringe programs should be made 
available to all populations including prison 
populations
Opportunistic IIIA
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All people aged 15–29 years 
of age if sexually active
All people aged ≥30 years 
and at high risk (see Table 
8.1)
Recommend nucleic acid amplification 
tests (NAAT) via:
•	 endocervical swab if having a 
speculum examination, or
•	 first void urine, or 
•	 self administered low vaginal swab




All pregnant women First visit
Pregnant women at high risk 
of STI (see Table 8.1)
First visit and again 
in third trimester
Women having a termination 
of pregnancy
Once





Sexually active people aged 
15–39 years and pregnant 
women where local 
prevalence rates are high 
(see reference 7)






Men who have sex with men Recommend throat swab NAAT and 
culture, plus anal swab NAAT and 
culture
Annually or 3–6 






All sexually active people 
aged <35 years where local 
prevalence rates are high 
(see Resources) 
Recommend NAAT for women (as 






All pregnant women Recommend testing with specific 
treponemal tests (EIA or TPPA or 
FTA-Abs) and non-specific treponemal 
tests (RPR). Liaise with local pathology 
providers to determine which tests are 
available for screening
At first visit 
Repeat at 28 
weeks if positive, in 
a high prevalence 
area or if risk 
factors for STIs are 
present
IIID
Men who have sex with men 
Others at high risk of STIs
Syphilis testing as above Annually IIB










Neonates Recommend HBV vaccination Once at birth prior to 
leaving hospital
ID
Babies born to mothers 
who are HBsAg positive
Recommend HBV immunoglobulin and 
vaccination at birth
Complete primary course of vaccination, 
followed by testing for anti-HBs and HBsAg at 




within 12 hours and 
vaccination (HBV) 
preferably within 24 
hours (definitely within 
7 days) of birth
IA
Unvaccinated people 
at high risk of STI/ BBV 
infection (see Table 8.1)
Recommend HBV vaccination 3 doses at 1 and  
6 months*
ID
Test healthcare workers, those at risk of 
severe or complicated disease, haemodialysis 
patients, sexual partners and household 
contacts of recently notified HBV carrier for 
seroconversion
4–8 weeks after the 
last dose
GPP
Individuals exposed to 
HBsAg positive individuals 
or unable to be identified 
and tested rapidly
Offer HBV post-exposure prophylaxis (HBIG 
and primary course of vaccination) for non-
immune people 
Initiate within 72 
hours (or 14 days for 
sexual contact)
IIC
People with HCV infection 
or chronic liver disease 
not immune to HBV





Girls/women prior to first 
sexual activity 
Females who are sexually 
active
Recommend HPV vaccination (see Chapter 
15, recommendations for cervical cancer 
prevention)
10–13 years of age: 
school-based
14–26 years of age at 




Men who have sex with 
men
Injecting drug users 
People with chronic HBV 
and HCV infection
Recommend hepatitis A vaccination 
if serology is negative (see Australian 
Immunisation Handbook)
Once GPP
Screening: HBV Non-vaccinated or 
vaccine status unknown 
People at high risk for 
BBVs
Healthcare workers
Offer individual HBV screening including: 
•	HBsAg ( a marker of acute or chronic 
infection)
•	HBsAb (a marker of immunity)
•	HBcAb (a marker of recent or past infection)
See Resources for guidelines on interpreting 
HBV tests
If serology is negative, offer HBV vaccination 
as above*
Opportunistic GPP
All pregnant women Recommend HBV screening to allow timely 
HBV vaccination and HBIG for infant at birth  
(see Chapter 9: Antenatal health)
At first antenatal visit III–3B
Screening: HCV People at high risk of 
contracting HVC infection 
(see Table 8.1)
Offer HCV serology testing As part of an annual 
health assessment 
IIIA
Infants born to HCV 
infected mothers
Offer HCV serology testing 18 months of age 
(repeated if positive)
IIA 
Screening: HIV Pregnant women Offer HIV serology testing At first antenatal visit IIB
Men who have sex with 
men and others at high 
risk of BBVs (see Table 8.1)
As part of an annual 
health assessment 
* Not subsidised on the National Immunisation Schedule but check relevant state/territory immunisation programs
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Table 8.1. Risk factors for STIs and bloodborne viruses
Risk factors for STIs Risk factors for BBVs
•	 Age <30 years
•	 Age <35 years and sexual network 
relates to a remote community
•	Multiple current partners
•	 Engaging in group sex
•	New partner
•	Using condoms inconsistently
•	 Living in an area with a high incidence 
of STIs
•	Having sex while under the influence of 
drugs and alcohol
•	Having sex in exchange for money or 
drugs
•	 Prison incarceration
•	 Victim of sexual assault
•	Men who have sex with men where any 
of the above risk factors are also present 
•	 Prison incarceration: current or past
•	Blood transfusion prior to 1990
•	 Tattoos or piercings not performed in a 
sterile professional setting
•	Cultural practices (ie. initiation 
ceremonies)
•	Current or past injecting drug use
•	Household member with HBV, HCV or 
HIV
•	 Sexual partner with HBV, HCV or HIV
•	 Infants of mothers infected with HCV, 
HBV or HIV
Source: Bradford D, Hoy J, Matthews G 200810
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Chapter 9: Antenatal care




Who is at 
risk?




Screening All pregnant 
women
Discuss and plan the schedule of antenatal visits with the 
pregnant woman based on her individual needs 
For an uncomplicated pregnancy review every 4 weeks until 
28 weeks, then every 2 weeks thereafter
At first antenatal 
visit
IB
Offer an ultrasound to determine gestational age and detect 
multiple pregnancies (best performed between 8 and 13 
weeks + 6 days gestation)
At first antenatal 
visit
IIIB
Measure blood pressure, height and weight and calculate 
BMI
At first antenatal 
visit
IIIB
Repeated weighing during pregnancy should be confined 
to circumstances where clinical management is likely to be 
influenced
Opportunistic GPP
Auscultate for heart murmurs, in areas with a high 
prevalence of rheumatic heart disease
At first antenatal 
visit
GPP
Advise women to have oral health checks and treatment if 
required (see Chapter 4: Dental health)
At first antenatal 
visit
IIB
Offer Pap test if due During first 
trimester
GPP
Offer testing for rubella immunity At first antenatal 
visit
IIB
Check blood group and antibodies At first antenatal 
visit and 28 
week visit
IB
Discuss the purpose and implications of testing for 
chromosomal abnormalities to promote an informed decision
In those wishing to proceed offer women first trimester 
combined screeningβ for chromosomal abnormalities 
between 11 and 13 weeks + 6 days gestation
Provide support to women in regional and remote areas 
to access this screening. If nuchal thickness ultrasound is 
unavailable, offer maternal serum screening† between 15 and 
17 weeks gestation
At first antenatal 
visit
IB





Offer proteinuria testing At first antenatal 
visit and each 
subsequent visit
IIB
Immunisation All pregnant 
women
Review influenza immunisation status and offer where 
appropriate (see Chapter 11: Respiratory health)
Opportunistic GPP
β   First trimester combined screening includes nuchal thickness ultrasound and plasma beta human chorionic gonadotropin (beta-HCG) 
and pregnancy associated plasma protein A (PAPP-A)
†   Maternal serum screening includes plasma maternal serum alpha fetoprotein (AFP), unconjugated oestriol and total human chorionic 
gonadotropin (HCG)
‡   Risk factors for pre-eclampsia include age >40 years, first or multiple pregnancy, BMI >30, diabetes, vascular or kidney disease, 
personal or family history of pre-eclampsia, raised blood pressure at first visit, pregnancy interval >10 years





Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All pregnant 
women
Regularly assess smoking status and remind 
patients to limit/avoid exposure to cigarette smoke




Record in the handheld pregnancy record (if 
available) or otherwise use local protocols to record 
this information
GPP
Behavioural Pregnant women 
who smoke
Offer interventions to assist smoking cessation 
ranging from brief advice to more intensive, 
multicomponent interventions (see Chapter 1: 
Lifestyle)














Consider nicotine replacement therapy (NRT) with 
discretion, noting that the safety of NRT in terms 
of effect on fetal development and birth outcomes 
remains unclear 
Discuss the risks and benefits taking into account 
overall clinical circumstances
If deemed necessary, intermittent forms of NRT 
are recommended rather than continuous use 
formulations to reduce the total dose of nicotine 
At each antenatal 
visit
IB




Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Pregnant women 
aged <25 years
Offer chlamydia testing with a nucleic acid 
amplification test (NAAT), most commonly by PCR, 
using either a first void urine, self obtained low 
vaginal swab or endocervical swab 





with a high 
prevalence of STIs 
Offer testing for chlamydia as above and consider 
testing for gonorrhoea
At first antenatal 
visit and consider 










with a high 
prevalence of STIs
Hepatitis C (HCV) testing is not routinely 
recommended. Screening may be discussed if 
there are identifiable risk factors for HCV infection 
(see Chapter 8: Sexual health, for risk factors)
Offer additional tests for syphilis infection
At 28 weeks 




Offer testing for asymptomatic bacteriuria with a 
midstream urine microscopy and culture
At first antenatal 
visit 
IA
In areas with limited access to pathology testing, 
dipstick urine tests may be used to exclude 
asymptomatic bacteriuria but positive results must 





Offer vaginal swab testing and treatment for 
asymptomatic bacterial vaginosis (eg. Gardnerella 
vaginalis, Bacteroides spp.)
Before 20 weeks 
pregnancy
GPP
Environmental Women with 
positive results 
for an STI or 
bloodborne virus
Ensure adequate recall systems are implemented 
for follow up 
Recommend partner treatment and contact tracing
(See Chapter 8: Sexual health and bloodborne 
viruses)
N/A GPP





Who is at risk? What should be done? How often? Level/ 
strength of 
evidence
Screening All pregnant 
women








Advise that not drinking alcohol is the safest 
option in pregnancy, particularly in the first 3 
months
At first and 
subsequent 






Advise women to avoid getting drunk
Advise women to have no more than two 
standard drinks on any 1 day and fewer than 
seven standard drinks in 1 week








Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All pregnant 
women
Offer a full blood examination to assess for 
anaemia
At first antenatal 









Consider testing for vitamin D levels, particularly in 
the non-summer months
At first antenatal visit GPP
Behavioural All pregnant 
women
Provide information on the benefits of a healthy diet 
in pregnancy and give practical, tailored advice on 
healthy eating








Recommend 500 mcg of folic acid daily to reduce 
the risk of newborn neural tube defects
At least 1 month 
prior to pregnancy 





Recommend a higher dose of 5 mg of folic acid 
daily to reduce the risk of newborn neural tube 
defects
At least 1 month 
prior to pregnancy 





proven vitamin D 
deficiency
Advise vitamin D supplementation – dose titrated 
according to clinical situation* (see Resources)
At diagnosis IIB
Pregnant women 
who are not iron 
deficient
Routine iron supplementation is not recommended N/A IB
Pregnant women 
with proven iron 
deficiency
Offer iron supplementation – oral or intramuscular 
– dose titrated according to clinical situation
At diagnosis  IB
All pregnant 
women
Offer iodine supplementation with 150 mcg/day 
(see Resources)
At first antenatal visit IIA
* Vitamin D supplementation is not subsidised under the Pharmaceutical Benefits Scheme





Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Pregnant women at 
risk of undiagnosed 
diabetes mellitus 
(BMI >30 kg/m2, 
family history of 
diabetes, previous 
gestational diabetes)
Measure fasting blood glucose
If not feasible, alternatives include random blood 
glucose or HbA1c (see Chapter 14: Type 2 





who do not have 
pre-existing diabetes
Perform a 75 g 2 hour oral glucose tolerance test 
(OGTT) for diagnosis of gestational diabetes (see 
Table 9.1 and Table 9.2)
Between 24 
and 28 weeks 
gestation
IA
If a 2 hour OGTT is consistently difficult to achieve, 
consider alternative tests such as a random blood 
glucose or a 50 g, 1 hour glucose challenge. If 






Perform a 75 g fasting OGTT At 6 weeks 
postpartum
GPP
Behavioural Pregnant women 
with diabetes
Offer advice and resources to promote good 
glycaemic control throughout pregnancy – 
encourage a healthy diet and exercise
Consider referral to specialist services, where 
available, and consult specific management 
guidelines for ongoing care (see Resources)
At diagnosis IA
Non-pregnant 
women who have 
had gestational 
diabetes in the past
Advise women of the future risk of developing 
diabetes and give advice about healthy diet, 
exercise and weight (see Chapter 1: Lifestyle)
Screen for diabetes with a fasting blood glucose 
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Table 9.1. The International Association of Diabetes and 
Pregnancy Guidelines for diagnosing pre-existing diabetes 
and gestational diabetes in pregnancy* 
Diagnostic criteria for pre-existing diabetes
One of the following measures of glycaemia is recommended for diagnosing  
pre-existing diabetes. If random plasma glucose is used, the diagnosis should be 
confirmed with either a fasting plasma glucose or HbA1c
Measure of glycaemia Consensus threshold
FPG (fasting plasma glucose) ≥7.0 mmo/L
Hb1c ≥6.5%
RPG (random plasma glucose) ≥11.1 mmol/L (confirmation with FPG/ HbA1c 
recommended)
Diagnostic criteria for gestational diabetes
Using a 75 g 2 hour oral glucose tolerance test, one or more of these values is 
diagnostic of gestational diabetes
Glucose measure Glucose concentration
FPG ≥5.1 mmol/L*
1 hour plasma glucose ≥10 mmol/L
2 hour plasma glucose ≥8.5 mmol/L*
* At the time of writing these criteria had not been published by the Australian Diabetes in   
  Pregnancy Society. Current criteria for gestational diabetes are FPG ≥5.4 mmol/L and 2 hour 
plasma glucose ≥7.9 mmol/L
Source: Metzger BE, Gabbe SG, Persson B, et al 201092 
Table 9.2. Current interpretive criteria for 75 g OGTT in 
pregnancy in Australia
Glucose measure Glucose concentration
Fasting Above 5.4
2 hour Above 7.9
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people aged 
15+ years
Screening for depression is not routinely 
recommended unless comprehensive support 
services are available (see Table 10.3 )
N/A IB
In the absence of services outlined in Table 10.3, 
useful support services include those provided 
by social and emotional wellbeing workers 
and Aboriginal mental health workers and 
psychologists with an understanding of the local 
context (see Resources)
GPP
If comprehensive support services are not 
available then assess for the presence of risk 
factors for depression (see Table 10.4)
GPP
People in whom 
depression risk 
is greater (see 
Table 10.4)
Take a patient history to assess mood and 
consider asking:
•	 ‘Over the past 2 weeks, have you felt down, 
depressed or hopeless?’ 
•	 ‘Over the past 2 weeks, have you felt little 
interest or pleasure in doing things?’
(See Table 10.1 for diagnostic criteria)
Opportunistic 1B
Behavioural All people aged 
15+ years
Behavioural interventions are not recommended 
for prevention of depression
N/A ID
Chemoprophylaxis All people aged 
15+ years
Medications are not recommended for primary 
prevention of depression
N/A GPP
Environmental All people aged 
15+ years
Community based psychosocial programs are 
not recommended for prevention of depression
N/A IC
Table 10.1. DSM-IV criteria for a depressive episode
•	 Five (or more) of the following symptoms have been present during the same 
2-week period and represent a change from previous functioning; at least one of the 
symptoms is either depressed mood or loss of interest or pleasure
•	Depressed mood most of the day, nearly every day
•	Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day
•	 Significant weight loss when not dieting or weight gain 
•	 Insomnia or hypersomnia nearly every day
•	 Psychomotor agitation or retardation nearly every day 
•	 Fatigue or loss of energy nearly every day
•	 Feelings of worthlessness or excessive or inappropriate guilt nearly every day 
•	Diminished ability to think or concentrate, or indecisiveness, nearly every day 
•	Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a 
suicide attempt or a specific plan for committing suicide
•	 In addition the episode must interfere with the person’s daily routine or relationships, 
and not have a cause such as alcohol or other drugs, a physical illness or the death of 
a loved one
Source: American Psychiatric Association 200013
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Table 10.2. Proportions of stresses reported in the previous 12 months, by 
Indigenous status, year and stressor type, Australia, 2004–05 and 2006
 Indigenous status/year
Indigenous Total population
Type of stressor 2004–06 2006
Death of a family member or friend 42 23
Serious illness or disability 28 30
Not able to get a job 17 13
Alcohol or drug related problem 25 8.6
Overcrowding at home 17 –
Members of a family sent to jail/in jail 19 –
Witness to violence 14 3.9
Trouble with police 16 3.9
Discrimination/racism 12 –
Any stressor 77 59
Source: ABS, 200640 ABS, 200731
Notes:  1. Proportions are expressed as percentages 
 2.  The total population for ‘serous illness or disability’ data has been estimated by adding proportions for the 
two sub-components, so may slightly overstate the true proportion
Table 10.3. Features of comprehensive support services associated 
with improved outcomes from depression screening
•	 An initial visit with a nurse specialist for assessment, education and discussion of patient preferences 
and goals
•	 A follow up visit with a trained nurse specialist and ongoing support for adherence to medication for 
those prescribed antidepressant medications
•	 A visit with a trained therapist for cognitive behavioural therapy
•	 A reduced copayment for patients referred for psychotherapy
•	 Professional support including the following:
 – staff and clinician training (1 or 2 day workshops)
 – availability of clinician manuals
 – monthly training lectures
 – academic detailing 
 – resource materials for clinicians, staff, and patients 
•	 Institutional financial commitment
Source: O’Connor EA, Whitlock EP, Beil TL, Gaynes BN 20095
Table 10.4. People at greater risk for depression
•	 Exposure to adverse psychosocial events, such as unemployment, divorce or poverty
•	 A previous history of depression or suicide attempts
•	 A history of physical or sexual abuse
•	 A history of substance abuse
•	 Presence of other chronic diseases, including chronic pain
•	Multiple presentations to health services may also be an indicator of depression. Factors that make it 
more likely that depression will be missed include:
 – limited consultation time
 – presentations of mostly physical or atypical symptoms
 –  health professional attitudes – eg. the belief that nothing can be done, or that depression is a 
normal response to stress
 – communication difficulties
Source: National Collaborating Centre for Mental Health and the Royal College of Psychiatrists 20106







Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people Screening for suicide risk is not routinely 
recommended 
N/A IC
People with any one of 
the following:
•	 past history of 
intentional self harm
•	 a history of mood 
disorders
•	 hazardous alcohol 
consumption or use 
of other recreational 
drugs
Consider asking about past and current 
suicidal ideation and intent as part of a 
comprehensive medical history
Opportunistic GPP
Behavioural All people No specific behavioural interventions are 
recommended for prevention of suicide
N/A IC
People at increased 
risk of suicide from 
history or clinical 
judgement
Consider local methods of enhancing effective 
contact with volunteer or professional 
agencies, particularly access to Aboriginal 
mental health workers
Ongoing IIIC
Chemoprophylaxis All people Medication is not recommended for the 
prevention of suicide beyond a clinically 
indicated use for diagnosed conditions (eg. 
major mental illness)
N/A IB
Environmental Communities Remove access to lethal methods of suicide 
both in the community and the household
Ongoing IC
Communities Advocate for community based health 
promotion programs that holistically address 
the multifactorial nature of social and 
emotional wellbeing (eg. sports events, caring 
for country programs, healthy lifestyle festivals)
Ongoing GPP
N/A Provide education for primary care health 
professionals to recognise and respond to 
psychosocial distress and depression
Ongoing IC
N/A Integrating mental health services with alcohol 
and other drug services can improve service 
access to youth who are at risk of suicide
Ongoing GPP
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Chapter 11: Respiratory health
Pneumococcal disease prevention




Who is at risk? What should be done? How often? Level/
strength of 
evidence
Immunisation Healthy adults aged ≥50 
years 
See also Chapter 
2: Child health, for 
childhood vaccination 
recommendations
Pneumococcal vaccine (23vPPV) 
is recommended for the prevention 
of invasive pneumococcal disease
Opportunistic 
A second vaccination is 
recommended 5 years 
later 
GPP
People aged 15–49 
years who are smokers 
or have an underlying 
high risk conditions (eg. 
chronic cardiac, renal or 
lung disease, diabetes, 
alcohol related problems, 
immunosuppression)
Pneumococcal vaccine (23vPPV) 
is recommended for the prevention 
of invasive pneumococcal disease
Opportunistic 
A second vaccination is 
required 5 years later
A third vaccination is 
recommended 5 years 
later or at 50 years of 
age (whichever is later)
IIC 
Environmental N/A Promote primary care, community 
based strategies to improve 
pneumococcal vaccination uptake 
and timeliness, particularly the 
implementation of reminder/recall 
systems
N/A IA
Communities Promote community awareness 
of benefits and timeliness of 
vaccines and enhancing access to 
vaccination services
 







Who is at risk? What should be done? How often? Level/
strength of 
evidence
Immunisation All people aged ≥15 
years
Offer influenza vaccine in the pre-flu 
season months for the prevention of 
influenza (March to April)
Annually GPP
Children with chronic 
illness aged 6 months 
to 14 years
Annually IIC
Women who are 
pregnant or planning a 
pregnancy 
Part of routine 
antenatal care 
(see Chapter 9: 
Antenatal care)
IIB
Healthcare providers Annually GPP
Children under 6 
months of age
Influenza vaccination is not recommended N/A GPP
Behavioural Household contacts of 
a person with influenza
Good hygiene practice, such as frequent 
handwashing and covering the mouth on 
coughing or sneezing, is recommended 
to decrease the spread of influenza, 
particularly to reduce transmission from 
children to other household members
Opportunistic IIIC
Healthcare workers Minimise exposure risk to patients with 
influenza-like illness by adhering to current 
infection control guidelines 
In addition to standard infection control 
procedures, personal protective 
equipment is recommended during 
influenza pandemics
N/A
Chemoprophylaxis Healthy adults Neuraminidase inhibitors (NIs) are 
generally not indicated for the prevention 
of influenza
N/A IIB
People at high 
risk of influenza 
complications, where 
there are high levels of 
circulating virus
Consider NIs for high risk individuals in 
close contact with someone with a proven 
case of influenza (ideally initiated within 48 
hours), particularly in a pandemic situation 
or where there is high levels of circulating 
virus
Opportunistic GPP
Environmental N/A Primary care, community based strategies 
to improve vaccination levels, particularly 
using reminder/recall systems, should be 
implemented
N/A IB
Communities Activities should also focus on increasing 
community awareness of benefits and 
timeliness of vaccines for vaccinations and 
enhancing access to vaccination services








Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people Routine screening for asthma is not 
recommended
Early detection strategies should be considered 
(eg. clinical vigilance, detailed history considering 
mimics of asthma, and spirometry when 
symptoms are suggestive)
N/A GPP
Behavioural Children Maternal dietary restrictions during breastfeeding 
or pregnancy are not recommended for the 
prevention of asthma
Opportunistic IIIB
All people A high intake of fruit and vegetables should be 




Children with seasonal 
rhino-conjunctivitis
Advise that immunotherapy is not currently 
recommended as a preventive strategy of 
asthma
N/A IIB
Environmental Children Strategies to provide a smokefree environment 
are recommended
Smoking cessation advice should be given to 
pregnant and breastfeeding women  
(see Chapter 9: Antenatal care)
Opportunistic IIIA
Advise families that avoidance of exposure to 
airborne allergens such as house dustmite or 
pets is not shown to be effective in preventing 
asthma
IIIB
Workers in high 
risk workplaces, 
where exposure to 
occupational dusts and 
chemicals are likely
Recommend use of respiratory protective 
equipment
N/A IIIB
*  Risk factors include a family history (particularly maternal) of asthma and allergies, a past history of atopy and food allergies in early life, 
obesity, low birthweight, in utero tobacco exposure, tobacco smoking, environmental tobacco smoke, environmental pollution and work 
related exposures55,57,63,64,81
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Chronic obstructive pulmonary disease
Recommendations: Chronic obstructive pulmonary disease
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence




Offer influenza vaccine in the pre-flu season 
months for the prevention of influenza (March 
to April)
Annually IIB 
Pneumococcal vaccine (23vPPV) is 
recommended for the prevention of invasive 
pneumococcal disease






Screening Current smokers 
Ex-smokers over 
35 years of age
Screen for symptoms of COPD (persistent 
cough/sputum production, wheezing, 
dyspnoea)
Opportunistic IIB
If symptoms are present spirometry is indicated 
to assess for COPD
Spirometry is not recommended to screen 
healthy adults who do not report respiratory 
symptoms
Opportunistic IA
Chest X-ray is not recommended for the 
diagnosis or screening of COPD
Chest X-ray may be of value to rule out other 
diagnoses and for later use as a baseline
Opportunistic GPP
Behavioural All people Advise of the importance of not smoking as the 
most effective strategy to prevent COPD (see 






Smoking cessation reduces the rate of decline 
of lung function. Counselling and treatment of 
nicotine dependence should be offered to all 
smokers regardless of the presence or absence 
of airflow obstruction (see Chapter 1: Lifestyle, 
smoking)
Opportunistic IA




Pharmacotherapy (bronchodilator treatment, 
inhaled corticosteroids, long term antibiotic 
treatment) does not modify decline in lung 
function
Pharmacotherapy is useful in decreasing 
symptoms and/or complications and improving 
quality of life
Opportunistic IA
Environmental All people Advise that risk factors for COPD should be 
minimised (eg. occupational exposure, ETS 
and indoor/outdoor air pollution and irritants). 
This may include strategies such as adequate 
ventilation when cooking with solid fuels 
and avoidance of irritants and reduction of 
emissions in the workplace
N/A IIIC
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Bronchiectasis and chronic suppurative lung disease
Recommendations: Bronchiectasis and chronic suppurative lung disease
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/strength of 
evidence
Immunisation All children and 
adults 














Ensure primary care provider review after the ARI 
episode 
If wet or productive cough* is present, consider 
the diagnosis of CSLD.† Recommence antibiotics 
and undertake investigations as per management 
guidelines94
3–4 weeks post 
episode then 2 




treatment of wet 
cough in children)
IIIB (screening for 




ARIs (particularly if 
hospitalised)
Consider a diagnosis of CSLD. Repeat a chest 
X-ray. Refer to specialist if:
•	 >2 episodes of chest X-ray proven pneumonia 
and/or 
•	 Chest X-ray persistently abnormal for >6 weeks
Opportunistic III (screening for 




(>2 months) wet 
cough 
Consider a diagnosis of CSLD. Assess with a 
chest X-ray and see above 
If wet or productive cough* is present, consider 
the diagnosis of chronic suppurative lung 
disease.† Recommence antibiotics and undertake 
investigations as per management guidelines94 
Annually IA (antibiotics 
efficacy in 
treatment of wet 
cough in children)




Behavioural All infants Promote and encourage breastfeeding At postnatal checks IIIB (breastfeeding 
protective)
All children Promote good hygiene practices to reduce 
burden of infections (see Chapter 7: Hearing loss)
Opportunistic GPP B
People with 
CSLD or known 
bronchiectasis
Assess cough severity, quality of life, and 
exacerbating factors. Undertake regular review 
to prevent and manage complications and 
comorbidities (see Table 11.1) 
3 monthly clinic 
review
6 monthly specialist 
review 
GPP B
Infants at risk 
of exposure to 
environmental 
tobacco smoke 
both in-utero and 
in the postnatal 
period
Advise and assist pregnant women to avoid 
smoking (See Chapter 9: Antenatal care)
Advise parents/carers who smoke about the 
harms of environmental tobacco smoke and the 
need to limit childhood exposure, particularly in 
confined spaces (eg. homes and motor vehicles) 
(see Chapter 1: Lifestyle, smoking)
Opportunistic IIIC
Mothers with or 
at risk of having 




Promote increased access to comprehensive 
antenatal care (see Chapter 9: Antenatal care)
Opportunistic GPP




Chemoprophylaxis People with 
CSLD or known 
bronchiectasis
Consider maintenance antibiotics on discussion 
with the person’s specialist
As per management 
guidelines94
GPP C
*  Cough is usually underreported;40 children do not usually produce sputum and hence the term wet cough (rather than productive cough) is used94
†  Bronchiectasis refers to chronic suppurative lung disease (CSLD) with the presence of high resolution chest CT (HRCT) radiological features.95 
CSLD is diagnosed when symptoms and/or signs of bronchiectasis are present with or without HRCT features.95 These symptoms and/or signs 
are: continuous, wet or productive cough for >8 weeks, ± other features such as exertional dyspnoea, reactive airway disease, recurrent chest 
infections, growth failure, clubbing, hyperinflation or chest wall deformity95 
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Table 11.1. Regular review of bronchiectasis
Regular review consists of: 
•	 assessment of severity, which includes oximetry and spirometry
•	 sputum culture
•	management of possible complications and comorbidities, particularly for 
gastro-oesophageal reflux disease, reactive airway disease/asthma, COPD, 
otorhinolaryngeal disorders and dental disease. Less commonly patients require 
assessments for sleep disordered breathing, cardiac complications and referral for 
lung transplantation
Source: Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al 201095
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Chapter 12: Cardiovascular disease prevention
Recommendations: For people without an established diagnosis of CVD
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Age 12–17 years Assess smoking status, physical activity, 
nutrition, BMI and waist circumference (see 
Chapter 1: Lifestyle)
Advise lifestyle risk reduction accordingly (see 
Chapter 1: Lifestyle)
Opportunistic 
and as part of 
an annual health 
assessment
GPP
Age 18–34 years 
without any vascular 
risk factors
Assess smoking status, physical activity, 
nutrition, BMI and waist circumference
Also assess BP, family history of premature 
CVD, diabetes risk (see Chapter 14: Diabetes 
prevention), psychosocial risk factors (see 
Chapter 10: Mental health) and socioeconomic 
risk factors 
Advise lifestyle risk reduction accordingly (see 
Chapter 1: Lifestyle)
Opportunistic 
and as part of 
an annual health 
assessment
GPP
Age 18–34 years and 
one or more of the 
following is present: 
family history of 
premature CVD 





Assess risk factors as above* 
Also assess serum lipids and screen for CKD 
(see Chapter 13: Chronic kidney disease 
prevention and management)
Advise lifestyle risk reduction accordingly (see 
Chapter 1: Lifestyle)
Opportunistic 
and as part of 
an annual health 
assessment
GPP
Age 35–74 years Assess for the presence of any Framingham, 
non-Framingham risk factors and clinically 
high risk conditions (see Table 12.1)
If no clinically high risk conditions are present 
then calculate absolute 5 year CVD risk using 
the Australian cardiovascular risk charts 
(Appendix 1) or the Framingham risk equation 
(FRE) calculator (see Resources)




to level of risk 
(see below)
IIB
Age over 74 years Assess for presence of any Framingham, non-
Framingham risk factors and clinically high risk 






Behavioural People with low 
absolute 5 year CVD 
risk (<10%)
Advise lifestyle risk reduction as needed for 







cereals, nuts and seeds, legumes, fish, lean 
meat, poultry, low fat dairy products and 
limiting saturated and trans fat intake
•		limit	alcohol	intake	to	≤2	standard	drinks/day
Review risk every 
2 years
IA 
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People with the 
following:
•	 absolute 5 
year CVD risk 
moderate or high 
(≥10%)
•	 presence of any 
clinically high risk 
conditions (see 
Table 12.1)
Advise lifestyle risk reduction as above






Chemoprophylaxis People at low 
absolute risk:
•	 <10% 5 year CVD 
risk and with 
BP persistently 
≥160/100 mmHg






People at moderate 
absolute risk:
•	 10–15% 5 year 
CVD risk
Review individual risk factor profile and 
recommend commencing a BP lowering 






People at high 
absolute risk: 
•	  >15% 5 year CVD 
risk or presence of 
any clinically high 
risk conditions 
(see Table 12.1)
Recommend commencing both a BP lowering 
medication and lipid lowering medication 






Aspirin is not routinely recommended IC
People with atrial 
fibrillation (AF) 
without prior CVD
Determine the cause of AF and manage rate 
and rhythm control. Assess and manage CVD 
risk as above. Consider oral anticoagulant 
treatment if valvular heart disease is present 
or two or more of the following risk factors are 










*  Although absolute CVD risk assessment is currently not recommended in Aboriginal and Torres Strait Islander people aged less than 35 
years, a multifactorial assessment of CVD risk factors is still recommended to guide management decisions. Treatment on the basis of 
elevated single risk factors may still be appropriate depending on the clinical context
**  Specific choice of BP and lipid lowering agents and guidelines on treatment targets is beyond the scope of this guideline. See 
Resources for links to specific management guidelines. If BP or lipid levels are extreme or non-responsive to treatment then further 
investigation for underlying causes is recommended
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Recommendations: For people with an established diagnosis of CVD
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening People with CVD Calculation of the absolute CVD risk using 
the FRE calculator is not recommended. 
Five year risk of a subsequent CVD event is 
assumed to be high
N/A
Behavioural People with CVD Intensive lifestyle risk factor management as 
for patients without an established diagnosis 
of CVD (see Table 12.1) 
Review at every visit 1A
A tailored cardiac rehabilitation program 
should be offered to all people post 
myocardial infarction (MI) and other acute 
coronary syndromes, and to those who have 
undergone revascularisation procedures 
Post CVD event 1A
Chemoprophylaxis People with CVD Commence BP lowering treatment at 
any BP level unless there is symptomatic 
hypotension*
Lifelong IA
Commence lipid lowering treatment with 
a statin at any cholesterol level unless 
contraindicated*
Lifelong IA
Commence low dose aspirin treatment 
(75–150 mg) unless contraindicated
Consider alternative antiplatelet agents 
such as clopidogrel (75 mg) if aspirin 
hypersensitivity is present
For people with ischaemic stroke 
combination aspirin/dipyridamole may also 
be considered
Lifelong IA
People with CHD 
with stent insertion 
or recent acute 
coronary heart 
disease 
Consider clopidogrel (75 mg) in combination 
with aspirin
For 12 months 
post stent insertion 
depending on 






Oral anticoagulant treatment is 
recommended if AF or cardio-embolic 
stroke is present unless contraindicated. 
Consultation of specific management 
guidelines is recommended (see Resources)
Lifelong IA
*  Specific choice of BP and lipid lowering agents and guidelines on treatment targets is beyond the scope of this guideline. See 
Resources for links to specific management guidelines. If BP or lipid levels are extreme or non-responsive to treatment then further 
investigation for underlying causes is recommended
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Table 12.1. Framingham and non-Framingham CVD risk factors
Framingham risk equation 
factors*† 
Non-Framingham risk equation 
factors‡ 








•	 Left ventricular hypertrophy 
(LVH)†
•	Obesity (BMI >30 kg/m2 and/or waist 
circumference >102 cm in men, >88 cm 
in women)
•	 Family history of CVD before age 55 
years in a mother, father or sibling
•	 Presence of albuminuria#
•	 Atrial fibrillation
•	 Impaired fasting glucose ≥6.1 mmol and 
<7.0 mmol or glucose intolerance (2 hour 
glucose ≥7.8 mmol and ≤11.0 mmol)
•	 Socioeconomic hardship
•	Depression or other psychosocial stress
•	 Excessive alcohol intake
•	 Extreme risk factor elevations (SBP 
≥180 or DBP ≥110, total cholesterol 
>7.5 mmol/L)
•	 Type 2 diabetes and age >60 years 
•	 Type 2 diabetes and albuminuria#
•	Moderate to severe chronic kidney 
disease (eGFR <45 mL/min/1.73 m2  
or persistent proteinuria)
•	 Familial hypercholesterolaemia
*  The 1991 Framingham risk equation is intended for people without CVD. The most recently recorded pre-treatment measures for 
blood pressure or lipids should be used to estimate CVD risk in people already receiving treatment. Where this is not possible, 
clinicians should make decisions on use of pharmacotherapy based on discussions with the patient and consideration of the 
individual context 
†  It is preferable to assess for LVH on the basis of echocardiography criteria rather than via an electrocardiogram 
‡  There are many additional risk factors that are independently associated with increased CVD risk such as C-reactive protein, 
coronary calcium scores, and plasma homocysteine levels. Measurement of such factors can be costly and invasive and there is 
limited evidence to suggest that assessment of these risk factors substantially improves risk prediction over those listed in Table 
12.1
§  Fasting lipid specimens are recommended, but a reasonable estimation of risk will be obtained from a non-fasting sample in most 
circumstances
#  Albuminuria is defined as an albumin excretion rate >20 mcg/min or urinary albumin to creatinine Ratio >2.5 mg/mmol in males  
and >3.5 mg/mmol in females
Sources: Framingham risk equation factors from Anderson K, Odell P, Wilson P, Kannel W 19916; non-Framingham risk equation 
factors from National Vascular Disease Prevention Alliance 2009 and Colagiuri S, Davies D, Girgis S, Colagiuri R 20097,31 and 
clinically high risk conditions from National Vascular Disease Prevention Alliance 20097
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Chapter 13: Chronic kidney disease prevention  
and management
Recommendations: Chronic kidney disease detection and management
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All adults aged 
18–29 years 
without any CKD 
risk factors
Screen for CKD risk factors (overweight or obesity, 
diabetes, elevated BP and smoking, family history 
of kidney disease)






with one of the 
following CKD 
risk factors:
•	 family history 








Screen for CKD with eGFR and urinary albumin-
creatinine ratio (ACR)
A first void specimen is preferred
If urine ACR is raised then repeat once or twice 
over 3 months. For further quantification consider 
collecting a timed specimen
Every 2 years (or 
more frequently 
if CVD risk is 






All people ≥30 
years
Behavioural Adults with any 
risk factors for 
CKD (see above) 
Offer individualised, structured education about 
risk factor avoidance and management
Annually IIIB
Offer smoking cessation support (see Chapter 1: 
Lifestyle, section on smoking)
Advise avoidance of exposure to environmental 
tobacco smoke
Opportunistic IIIB
Encourage regular physical exercise appropriate 
to their physical ability and medical history (see 
Chapter 1: Lifestyle, section on physical activity)
Opportunistic IIB
If overweight or obese encourage weight loss 
Offer group diet and exercise sessions if available, 
especially for patients with type 2 diabetes (see 
Chapter 1: Lifestyle, section on overweight/
obesity)
Opportunistic IB
Advise to limit dietary sodium intake to 100 mmol/
day (6 g salt per day) or less 
Opportunistic IIIB
Adults with CKD 
stages 1–3 (see 
Table 13.1)
Lifestyle risk factor management as above
Patients with CKD should be advised not to use 
salt substitutes that contain high amounts of 
potassium salts
Opportunistic As above 
for each risk 
factor
Advise consuming the recommended daily intake 
of protein for adults (0.75 g/kg/day)
Opportunistic IIC
A daily fluid intake of 2–2.5 L (including the fluid 
content of foods) is generally sufficient, although 
this might need to be varied according to individual 
circumstances 
Opportunistic IIIC
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Chemoprophylaxis All people with 
CKD
Regularly review medications to identify and avoid 
those with potential nephrotoxicity
Advise patients taking an angiotensin converting 
enzyme (ACE) inhibitor or angiotensin II receptor 
blocker (ARB) plus diuretic to avoid non-steroidal 







Adults with CKD 
and albuminuria 
(see Table 13.2)
Commence treatment with an ACE inhibitor 
or ARB, regardless of BP level. The goal is 
>50% reduction in albumin excretion without 
symptomatic hypotension
Alternative agents include calcium channel 
blockers
At diagnosis IA
An ACE inhibitor and an ARB should not normally 
be prescribed together
IIB
Adults with CKD 
and diabetes
Commence treatment with an ACE inhibitor or 
ARB regardless of BP level
At diagnosis IA
Blood glucose control in patients with CKD and 
diabetes should be optimised, generally aiming for 
an HbA1c target of 7%
Opportunistic IA
Adults with CKD 
and elevated BP
Consider use of more than one drug to achieve 
adequate BP control. (The number of drugs 
required tends to increase with declining GFR)
Opportunistic 
BP check at 
every visit
IIIB
If prescribed a BP lowering medication aim for a 
target of <140/90 mmHg, or <130/80 mmHg in the 
presence of micro- or macro-albuminuria (with or 
without diabetes)
IB
Adults with CKD Statins should be prescribed according to level 
of overall cardiovascular risk (see Chapter 12: 







Support the implementation of population based 
strategies for reduction of scabies and pyoderma 
among children (see Chapter 2: Child health and 
Chapter 5: Rheumatic heart disease)
N/A IIIB
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Table 13.1. Stages of chronic kidney disease
Stage Description GFR
(mL/min/1.73 m2)
1 Kidney damage* with normal or increased GFR >89
2 Kidney damage* with mild reduced GFR 60–89
3A Moderately reduced GFR 45–59
3B Moderately reduced GFR 30–44
4 Severely reduced GFR 15–29
5 Kidney failure <15 or dialysis
*  Kidney damage includes pathological abnormality or a marker of damage such as 
abnormalities in blood tests, urine tests or imaging studies1
Table 13.2. Definitions of normal albumin excretion, microalbuminuria 
and macroalbuminuria
Gender Normal albumin 
excretion
Microalbuminuria Macroalbuminuria
Urinary ACR Male <2.5 mg/mmol 2.5–25 mg/mmol >25 mg/mmol
Female <3.5 mg/mmol 3.5–35 mg/mmol >35 mg/mmol
Urinary albumin 
excretion per 24 
hours
Either <30 mg/24 hr 30–300 mg/24 hr > 300 mg/24 hr
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Chapter 14: Type 2 diabetes prevention and  
early detection
 Recommendations: Diabetes prevention and early detection
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Adults ≥18 years from 
regions with a high 
prevalence of diabetes 
(≥5%) 
AND/OR
Adults with any of the 
following high risk 
conditions:
•	 previous IGT or IFG
•	 history of gestational 
diabetes mellitus
•	 history of polycystic 
ovary syndrome
•	 history of 
cardiovascular disease
•	 current antipsychotic 
medication use
Measure fasting plasma glucose or random 
venous blood glucose 
A laboratory test is preferable, but finger prick 
testing is an alternative. HbA1c may also be 
used as a screening test for the diagnosis of 
diabetes*
Perform oral glucose tolerance test in those 
with equivocal results as above
The 2006 WHO/International Diabetes 
Federation criteria should be used to diagnose 
type 2 diabetes, IGT and IFG (see Table 14.1)
Annually as part 
of an adult health 
assessment
IIB
All adults ≥18 years 
from regions with a low 
population prevalence for 
diabetes (<5%)
Consider screening using AUSDRISK tool 
to determine if blood testing is required (see 
Resource)
If AUSDRISK score is ≥12 then proceed as 
above for high risk populations
Annually as part 
of an adult health 
assessment
IIIB
People <18 years with 
overweight/obesity
Consider the potential for early onset type 
2 diabetes and consider testing according 
to clinical context (see Chapter 1: Lifestyle, 
section on overweight/obesity)
Opportunistic GPP
Behavioural All people Measure BMI and waist circumference
Advise minimum of 30 minutes moderate 
activity on most days
Encourage diet rich in vegetables, fruits, 
legumes, high fibre cereals, fish, and lean 
meats. Limit fats, salt, sugar, alcohol
Opportunistic 
and as part of 
an annual health 
assessment
IA
For people overweight or obese (see 
recommendations in Chapter 1: Lifestyle, 
section on overweight/obesity)
Mothers of young babies Encourage infant breastfeeding (see Chapter 
2: Child health)
People with BMI ≥35 kg/
m2
Advise intensive lifestyle modification as above
Discuss risks and benefits of bariatric 
surgery and consider referral if services are 
available (see Chapter 1: Lifestyle, section on 
overweight/obesity)
Opportunistic IIIC
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 Recommendations: Diabetes prevention and early detection (continued)
Chemoprophylaxis People with a high risk 
condition (see above) or 
at high risk of diabetes 
based on an AUSDRISK 
score ≥15
Advise intensive lifestyle modification as above
If lifestyle modification is unable to be 
achieved, the use of metformin, acarbose, 
rosiglitazone or orlistat has been shown to 
delay or prevent the onset of diabetes 
These medications all have potential risks (in 
particular rosiglitazone). None is PBS funded 
for people without diagnosed diabetes, so 
their use is not recommended at present 
Opportunistic 1B
Environmental Communities Advocate for multifactorial and coordinated 
community based interventions to increase 
access to healthy and nutritious food and 
promotion of increased physical activity (see 
Chapter 1: Lifestyle, section on physical 
activity)
N/A GPP
* HbA1c testing for the purpose of diagnosing diabetes cannot currently be claimed from Medicare
Table 14.1. Diagnostic criteria for type 2 diabetes and 
intermediate hyperglycaemia
Type 2 diabetes
Fasting plasma glucose* ≥7.0 mmol/L or
Random venous glucose (point of care)* ≥11.1 mmol/L or
2-hr plasma glucose† ≥11.1 mmol/L or
Glycated haemoglobin (HbA1c)‡ ≥6.5%
Impaired glucose tolerance (IGT)
Fasting plasma glucose <7.0 mmol/L and
2-hr plasma glucose† ≥7.8 and <11.1 mmol/L
Impaired fasting glucose (IFG)
Fasting plasma glucose 6.1–6.9 mmol/L and if measured
2-hr plasma glucose† <7.8 mmol/L
Non-diabetes 
Fasting plasma glucose ≤6.0 mmol/L or
Random venous glucose (point-of-care) ≤6.0 mmol/L
*  The diagnosis of type 2 diabetes requires two positive blood tests on separate days unless the 
plasma glucose is unequivocally elevated in the presence of acute metabolic decompensation or 
obvious symptoms such as excessive thirst and polyuria
†  Venous plasma glucose 2-hr after ingestion of 75 g oral glucose load. If 2-hr plasma glucose is 
not measured, status is uncertain as type 2 diabetes or IGT cannot be excluded 
‡  Currently recommended in some, but not all guidelines. HbA1c is not funded by Medicare for the 
initial diagnosis of diabetes 
Source: Colagiuri S, Davies D, Girgis S, Colagiuri R 20091
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Chapter 15: Prevention and early detection of cancer 
Prevention of cervical cancer








Immunisation Girls aged 10–13 
years
Promote human papilloma virus (HPV) 
vaccination for the prevention of cervical cancer 
ideally prior to the onset of sexual activity 
Recommend HPV vaccination as part of school 
based vaccination programs. If not accessed 
in a school program then offer through clinic/
community services
As per National 
Immunisation Program 
Schedule (NIPS) 
(varies between states 
and territories)
IIB
Girls aged 14–18 
years
Promote HPV vaccination for the prevention 
of cervical cancer ideally prior to the onset of 
sexual activity*




Women aged 19–26 
years
Promote HPV vaccination for the prevention of 
cervical cancer for health benefit, but likely to 
be less effective*
Women aged 27–45 
years
HPV vaccination may be of some benefit 
depending on sexual history† 
Screening Women aged 18–69 
years who have ever 
been sexually active
Offer Pap test screening from 18–20 years 
or 1–2 years after first sexual intercourse 
(whichever is later) regardless of whether HPV 
vaccination has been given
Every 2 years IIA
Women aged 70+ 
years who have ever 
been sexually active
Offer Pap test screening to women who have 
never had a Pap test or who request a Pap test
Pap test screening 
may cease for women 
aged 70 years who 
have had two normal 
Pap smears within the 
past 5 years
IIA
Women at higher risk 
(eg. previous cervical 
abnormalities, 
immune suppression, 
in utero exposure to 
diethylstilboestrol)
Offer Pap test screening Management regimen 
is complex: see 
NHMRC guidelines
GPP
Women who have 
been previously 
treated for high 
grade squamous 
intraepithelial lesion 
Offer annual Pap test screening combined with 
cervical HPV testing for 2 or more consecutive 
years, if not already done following specialist 
treatment
If both tests are 
negative in 2 
consecutive years, 
screening for average 
risk population can 
recommence
IIIC
Behavioural All women Assess smoking status and advise on 
increased risks of cervical dysplasia and 
cervical cancer (see Chapter 1: Lifestyle, 
section on smoking)
As part of an annual 
health assessment
IIIB
Offer a sexual health review (see Chapter 8: 
Sexual health and bloodborne viruses)
As part of an annual 
health assessment
*  Currently not subsidised through the NIPS
†  4-valent HPV vaccine (Gardasil®) is not registered by the Therapeutic Goods Administration for use in this age group due to lack of safety 
and efficacy data at the time of writing this guideline
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Prevention and early detection of liver  
(hepatocellular) cancer
Recommendations: Liver cancer prevention and detection
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/ 
strength of 
evidence
Immunisation All people Review if hepatitis B vaccination is indicated 
(see recommendations in Chapter 8: Sexual 
health and bloodborne viruses and Chapter 2: 
Child health)
See Chapter 8 See Chapter 
8
Screening All people Review if hepatitis B and C screening is 
indicated (see recommendations in Chapter 8: 
Sexual health and bloodborne viruses)







Recommend specialist review to consider if 
screening for hepatocellular carcinoma using 
alpha fetoprotein (AFP) and ultrasound is 
warranted
6–12 monthly as 
part of specialist 
management plan
IIIC
Behavioural Adolescents and 
adults
Assess levels of alcohol consumption 
and advise about safer levels of alcohol 
consumption to reduce long terms risk of 
alcohol related harm (see Chapter 1: Lifestyle, 
section on alcohol and Chapter 3: The health 
of young people)







Advise of the risks of liver disease and 
promote weight reduction strategies (see 
Chapter 1: Lifestyle, section on overweight/
obesity)
Opportunistic GPP
People at higher 
risk of hepatitis B 
or C infection (see 
Table 15.1)
Provide counselling on harm minimisation and 
promote peer education strategies around 
safer sex and injecting drug use where 
relevant (see Chapter 8: Sexual health and 
bloodborne viruses)
Opportunistic 
and as part of 








Provide counselling regarding risks of alcohol 
consumption
6–12 monthly as 
required
GPP
Chemoprophylaxis People with 
chronic hepatitis 
B† or hepatitis C 
infection
Assess disease severity and suitability for 
antiviral treatment
Regular monitoring for disease progression is 
recommended
Refer to national or local guidelines for 




or contact local 
services for advice
IIIC
*   The World Health Organization recommends screening and hepatitis B vaccination for all people from geographic areas with a 
prevalence of hepatitis B of >2%.30,31 The prevalence of hepatitis B infection in the Aboriginal population has been estimated to be 2% 
in the urban areas and 8% in rural areas2 
† Hepatitis B surface antigen positive >6 months
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Table 15.1. Risk factors for hepatitis B and C infection
Those at higher risk of hepatitis B infection include non-immune household or sexual 
contacts of people with acute or chronic hepatitis B; people aged 15–30 years; babies 
born to mothers with hepatitis B infection; people with multiple sexual partners; men 
who have sex with men; people who inject drugs; people at occupational risk or in 
prison/detention; and people with chronic liver disease, hepatitis C infection, HIV or 
impaired immunity
Those at higher risk of hepatitis C infection include people who have ever injected drugs 
for recreational purposes; people who have ever been incarcerated; those with tattoos 
and body piercings; recipients of blood products, tissues or organs prior to February 
1990 in Australia or anytime overseas; and sexual partners of those with hepatitis C 
infection if blood has been associated with sexual activity
See also Chapter 8: Table 8.1: Risk factors for sexually transmissible infections and bloodborne 
viruses
Sources: National Health and Medical Research Council 2008 and Department of Health and 
Ageing 201010,29
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
Prevention and early detection of cancer
70
Prevention and early detection of breast cancer
Recommendations: Breast cancer prevention and detection
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/strength 
of evidence
Screening All women Ask about family history of breast cancer to 
ascertain the individual risk of developing 
breast cancer (see Table 15.2)




Discuss ‘breast awareness’ rather than 
promoting regular breast self examination (ie. 
‘get to know what your breasts normally look 
and feel like’) and ask women to promptly 
report persistent or unusual changes
IIC
Women aged 
40–49 years at 
or slightly above 
average risk (see 
Table 15.2)
Routine mammographic screening is not 
recommended
If requested, provide information about 
mammographic screening to allow an 








Consider annual mammography starting at 
age 40 years
Consider referral to family cancer clinic or 
specialist cancer clinic where available for 
initial assessment of risk of developing cancer. 
This includes advice on the role of genetic 
testing, strategies to reduce risk of cancer, 




50–69 years at 
or slightly above 
average risk (see 
Table 15.2)
Recommend mammography screening and 
provide information to allow an informed 
decision based on individual risk and 
preferences





(see Table 15.2) 
Recommend routine mammography 
screening
Consider referral to family cancer clinic* or 
specialist cancer clinic for initial assessment
Every 2 years GPP
Women at 
potentially high 
risk of breast 
cancer (see Table 
15.2)





Offer referral to a family cancer clinic* for risk 
assessment, possible genetic testing and 
development of a management plan
When calculated 
to be at 
potentially high 
risk, and as 
needed 
GPP
Consider MRI breast screening in addition to 
mammography if aged <50 years. (Specialist 






Consider clinical breast examination As part of a well 
women's check
GPP
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Behavioural All women Promote physical activity as physical inactivity 
increases the risk of breast cancer (see 
Chapter 1: Lifestyle, section on physical 
activity)
As part of an 
annual health 
assessment 
(see Chapter 1: 
Lifestyle)
IIIB
Advise that alcohol consumption increases 
the risk of breast cancer, and that if alcohol 
is consumed it should be done at safe levels 
(see Chapter 1: Lifestyle, section on alcohol)
IIIB
Advise that cigarette smoking increases the 
risk of breast cancer, and support people 
who smoke to quit (see Chapter 1: Lifestyle, 
section on smoking)
 IIIC
Advise that maintaining a healthy weight 
lowers the risk of breast cancer (see Chapter 





Advise that breastfeeding has been shown to 
reduce the risk of breast cancer, and support 
women to breastfeed their infants (see 










Advise about risks and benefits of combined 
HRT; in particular advise about increased risk 





HRT and every 




Chemoprophylaxis Women at 
potentially high 
risk, and women 
aged >35 years 
at moderate risk
Consider specialist referral to discuss 
preventive treatment with tamoxifen or 
raloxifene
Use is not currently approved for subsidy 
under the Pharmaceutical Benefits Scheme 
for the primary prevention of breast cancer 
(see Resources)
IIID
*  Family cancer clinics provide counselling and information for families with a history of cancer on inheriting cancer, individual risk, 
screening, cancer risk reduction strategies, and genetic testing where appropriate. Clinics are conducted through the public 
hospital system and there is no direct cost to the patient for consultation or genetic testing. Location of family cancer clinics in 
Australia can be found at www.cancer.org.au/File/Aboutcancer/Family_Cancer_Clinics_31OCT06.pdf
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Table 15.2. Risk categories for breast cancer based on family history
Category 1
At or slightly above average 
risk (no more than 1.5 times the 
population average risk)
Category 2
Moderately increased risk 
(1.5–3 times the population 
average risk)
Category 3
Potentially high risk (may be 
more than 3 times the population 
average risk)
No confirmed family history of 
breast cancer
One first degree relative diagnosed 
with breast cancer at age 50 years 
or older
One second degree relative 
diagnosed with breast cancer at 
any age
Two second degree relatives 
on the same side of the family 
diagnosed with breast cancer at 
age 50 years or older
Two first degree or second degree 
relatives diagnosed with breast 
cancer, at age 50 years or older, 
but on different sides of the family 
(ie. one on each side of the family)
One first degree relative 
diagnosed with breast cancer 
before the age of 50 years 
(without the additional features 
of the potentially high risk group 
– see category 3)
Two first degree relatives, on 
the same side of the family, 
diagnosed with breast cancer 
(without the additional features 
of the potentially high risk group 
– see category 3 )
Two second degree relatives, 
on the same side of the family, 
diagnosed with breast cancer, 
at least one before the age of 
50 years, (without the additional 
features of the potentially high 
risk group – see category 3)
Two first degree or second degree 
relatives on one side of the family 
diagnosed with breast or ovarian 
cancer plus one or more of the 
following on the same side of the 
family:
•	 additional relative(s) with breast or 
ovarian cancer
•	 breast cancer diagnosed before 
the age of 40 years
•	 bilateral breast cancer
•	 breast and ovarian cancer in the 
same woman
•	 Jewish ancestry
•	 breast cancer in a male relative
One first degree or second degree 
relative diagnosed with breast 
cancer at age 45 years or younger 
plus another first degree or second 
degree relative on the same side of 
the family with sarcoma (bone/soft 
tissue) at age 45 years or younger
Member of a family in which the 
presence of a high risk breast cancer 
or ovarian cancer gene mutation has 
been established
Source: National Breast and Ovarian Cancer Centre 201043
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Prevention and early detection of colorectal  
(bowel) cancer
Recommendations: Colorectal cancer prevention and detection
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/strength 
of evidence
Screening All people Ask about family history of colorectal 
cancer (see Table 15.3) in order to 
estimate the individual risk of developing 
colorectal cancer 
As part of an annual 
health assessment 
GPP
People at or 
slightly above 
average risk 
age 50+ years 
(category 1: 
Table 15.3)
Consider faecal occult blood test 
(FOBT)* and refer all abnormal results for 
appropriate diagnostic evaluation
Every 2 years from 
age 50–75 years, and 
could be continued 
beyond 75 years 







Consider referral for colonoscopy
(Flexible sigmoidoscopy and double 
contrast barium enema or CT 
colonography may be offered if 
colonoscopy is contraindicated)
Every 5 years starting at 
age 50 years, or at an 
age 10 years younger 
than the age of first 
diagnosis of bowel 





risk (category 3: 
Table 15.3)
Consider referral to a specialist service 
for further risk assessment and 
possible genetic testing, and to a bowel 
cancer specialist to plan appropriate 
surveillance
(See Resources for specific 
recommendations for screening for 
those with FAP or HNPCC)**
At the time of 
determining the 
individual is at high risk
Offer referral later 
if not done at initial 
assessment
IIIC
Past history of 
adenoma
Undertake surveillance colonoscopy Timeframe for 
surveillance 
colonoscopy varies  
(see Resources)
IA
Behavioural All people Provide lifestyle risk factor counselling 
on the benefits of regular physical 
activity, maintaining healthy weight, 
alcohol intake in the low risk range, 
avoidance of tobacco smoking, 
restricting energy intake and dietary fat 
(see Chapter 1: Lifestyle) 
Also recommend consuming only 
moderate amounts of red meat, 
minimising consumption of charred 
and processed meats, and consuming 
vegetables and dietary fibre as these 
foods may be protective








Consider prophylactic aspirin use (in 
consultation with a specialist)
At time of diagnosis with 
colorectal adenoma
IIC
*  Free, one-off FOBTs are offered to people turning 50, 55 or 65 years between January 2011 and December 2014. GPs can also refer 
patients for examination of faecal specimens for occult blood under Medicare Benefits Schedule (Items 66764, 66767 and 66770)
** Familial adenomatous polyosis (FAP); hereditary non-polyosis colorectal cancer (HNPCC)
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Table 15.3. Risk categories for colorectal cancer based on family history
Category 1
Those at or slightly above 
average risk based on 
family history 
Category 2
Those at moderately 
increased risk based on 
family history 
Category 3 
Those at potentially high risk based on 
family history 
No personal history of 
colorectal cancer, colorectal 
adenomas or chronic 
inflammatory bowel disease 
and no confirmed close family 
history of colorectal cancer 
OR
One first degree (parent, 
sibling, child) or second degree 
(aunt, uncle, niece, nephew, 
grandparent, grandchild) 
relative with colorectal cancer 
diagnosed at age 55 years or 
older
OR
Two relatives diagnosed with 
colorectal cancer at age 55 or 
older but on different sides of 
the family
One first degree relative with 
colorectal cancer diagnosed 
before the age of 55 years 
(without potentially high risk 
features as in category 3) 
OR
Two first or one first and one 
second degree relative/s 
on the same side of the 
family with colorectal cancer 
diagnosed at any age 
(without potentially high risk 
features as in category 3)
Three or more first degree relatives or a 
combination of first and second degree 
relatives on the same side of the family 
diagnosed with colorectal cancer 
OR
Two or more first or second degree relatives 
on the same side of the family diagnosed with 
colorectal cancer plus any of the following high 
risk features:
•	multiple colorectal cancers in a family 
member
•	 colorectal cancer before the age of 50 years
•	 a hereditary non-polyposis colorectal cancer 
(HNPCC) related cancer (endometrial, 
ovarian, stomach, small bowel, renal pelvis 
or ureter, biliary tract, brain cancer)
OR
•	 at least one first degree or second degree 
relative with a large number of adenomas 
throughout the large bowel (suspected 
familial adenomatous polyposis (FAP)
OR
•	member of a family in which a gene mutation 
that confers a high risk of colorectal cancer 
has been identified
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Early detection of prostate cancer
Recommendations: Prostate cancer prevention and detection
Preventive 
intervention type
Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Men at average 
risk
The decision to conduct prostate 
specific antigen (PSA) testing 
and digital rectal examination 
(DRE) should be individualised as 
population based screening is not 
recommended 
Opportunistic IIID
Men at potentially 
higher risk due to 
family history
Opportunistic IID
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
Prevention and early detection of cancer
76





Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All postmenopausal 
women and men over 
50 years of age
Assess risk factors for osteoporosis (see 
Table 16.1)




People at moderate and 
high risk (see Table 16.1)
Recommend dual energy X-ray 
absorptiometry (DXA) to determine bone 
mineral density (BMD)
If DXA confirms osteoporosis then manage 
as high risk
At baseline, 
then 2 yearly if 
needed
IA 
Behavioural All postmenopausal 
women and men over 
50 at all levels of risk
Advise adequate dietary calcium intake: 
1300 mg/day for women over 50 and men 
over 70; 1000 mg/day for men 50–70 
years
Opportunistic 
and as part of 
an annual health 
assessment
IA
Recommend smoking cessation (see 
Chapter 1: Lifestyle, section on smoking)
Recommend maintenance of a healthy 
weight and body mass index (see Chapter 
1: Lifestyle, section on overweight/obesity)
IA
Advise adequate but safe sunlight 
exposure as a source of vitamin D*
GPP
People at average and 
moderate risk (see Table 
16.1)
Advise regular high intensity weightbearing 
exercise for postmenopausal women and 
older men aiming to achieve a target of 
30 minutes/day on most days of the week 
(see Chapter 1: Lifestyle, section on physical 
activity)
Opportunistic 
and as part of 
an annual health 
assessment
1A
People at high risk (see 
Table 16.1)
Advise regular low impact weightbearing 
exercise as part of a tailored program 
emphasising improved balance and 
flexibility
Opportunistic 
and as part of 
an annual health 
assessment
GPP
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Chemoprophylaxis All postmenopausal 
women and men over 
50 at all levels of risk
Consider calcium supplementation for 
those with inadequate dietary intake
Also consider vitamin D supplementation 
for those with inadequate sunlight 
exposure, particularly those in residential 
care
Opportunistic 
and as part of 
an annual health 
assessment
ID
People at moderate and 
high risk (see Table 16.1)
Consider bisphosphonates† in 
conjunction with calcium and vitamin D 
supplementation
At diagnosis IA 
Consider hormone replacement therapy 
to increase BMD and reduce fracture 
risk. Long term use is not recommended 
due to increased potential for harm, 




See management guidelines for further 
information§
IIC
People at high risk (see 
Table 16.1)
If the above medications are ineffective 
or contraindicated consider selective 
oestrogen receptor modulators (raloxifene) 
or parathyroid hormone (teriparatide)
See management guidelines for further 
information§
At diagnosis IIC
Environmental People at moderate and 
high risk
Consider a multifactorial falls reduction 
program (see Falls recommendations 
below)
At diagnosis ID
*  Fair-skinned people in Australia can produce adequate vitamin D with sun exposure to their face, arms and hands for a few minutes 
either before 10 am or after 3 pm on most days of the week. In winter in southern parts of Australia this exposure may need to be longer. 
People with darker skin generally require more sun exposure16
†  Bisphosphonates are subsidised under the PBS for the following conditions: concurrent use of oral corticosteroids (>7.5 mg/day) for 
3 months or more and a BMD T-score of –1.5 or less, women aged ≥70 years with a BMD T-score of –2.5 or less, any person with a 
radiologically confirmed fracture due to minimal trauma
‡  Strontium is subsidised under the PBS for the following conditions: women aged >70 years with a BMD T-score of –3.0 or less, all people 
with a radiologically confirmed fracture due to minimal trauma
§  Refer to clinical practice guidelines for specific treatment recommendations19
  Selective oestrogen receptor modulators and teriparatide are not subsidised under the PBS in the absence of a fracture due to minimal 
trauma. Recommend review the PBS for specific criteria
Table 16.1. Risk levels for osteoporosis
Average risk Moderate risk High risk
All postmenopausal women 
and men over 50 years of 
age
Age 60–70 years and any of the following:
•	 family history of osteoporotic fractures
•	 hypogonadism
•	 prolonged glucocorticoid use (>3 months) 
•	 inflammatory conditions




•	 history of a fall 
•	 age over 70 years
•	 Previous fracture due to 
minimal trauma
•	 Vertebral fractures
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening All people aged ≥50 
years at all risk levels
Assess for risk factors for falls (see Table 16.2) Annually IA 
Residents of aged 
care facilities (RACFs)
RACF staff should screen for risk factors for falls 
to allow for an individualised fall prevention plan
6 monthly IIB
People with a past 
history of falls
Recommend a detailed assessment including 
the following:
•	 cardiac and neurological disease assessment
•	medication review
•	 assessment of vision, gait and balance
•	 home environment assessment
Opportunistic IA 
Those with falls 
due to carotid sinus 
hypersensitivity 
Consider referral for pacemaker insertion As needed IIC
Those with vision 
threatening cataract 
disease
Referral for cataract surgery As needed IIC
Behavioural All people aged ≥50 
years
Recommend exercise which may include the 
following modalities: 
•	multicomponent group exercise (defined 
as targeting at least two of the following: 
strength, balance, endurance and flexibility) 
•	 tai chi as a group exercise 
•	 individually prescribed exercise to be carried 
out at home as per Australian physical activity 
guidelines (see Chapter 1: Lifestyle, section 
on physical activity)
As part of an annual 
health assessment
IA
People at high risk Recommend gait, balance and functional 
coordination exercises as part of a multifactorial 
intervention 
As part of an annual 
health assessment
IIC
Chemoprophylaxis People aged ≥50 
years with known 
vitamin D deficiency 
or inadequate 
exposure to sunlight
Consider vitamin D supplementation (see also 
osteoporosis section)
As part of an annual 
health assessment
IC
People at high risk 
taking medications
Review medications At least annually and 
recommend 6 monthly 
for people taking four 
or more medications
IIB
If taking psychotropic medications review the 
indications and consider gradual withdrawal if 
clinically appropriate
Opportunistic and as 
part of an annual health 
assessment
IIC
Consider home medication review by a 
pharmacist
Annually or when there 
is a clinical need 
IIB
People in RACFs Arrange medication review by a pharmacist Annually IIA 
Consider vitamin D supplementation Ongoing IA
Environmental All people aged >50 
years not at high risk
Home assessment and intervention is not 
recommended
N/A IA 
People at high risk Arrange for home assessment and intervention 
involving a multidisciplinary team
One-off for those with 
poor vision; opportunistic 
for all others
IIC
People in RACFs who 
are at high risk of falls
Consider use of hip protectors Opportunistic IIB
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Table 16.2. Risk factors for falls
•	 Increasing age
•	 Past history of falls
•	Neurological conditions: stroke, Parkinson disease, peripheral neuropathy
•	Multiple medications
•	 Psychotropic medications





•	 Fear of falling
•	 Low levels of physical activity
Source: The RACGP 200924
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Who is at risk? What should be done? How often? Level/
strength of 
evidence
Screening Asymptomatic people Dementia screening is not routinely 
recommended
N/A IIIC
People with symptoms 
such as memory loss 
or behaviour change, or 
if there are concerned 
family members
Consider administration of one of the following 
cognitive screening tests:
•	Mini Mental State Examination
•	General Practitioner Assessment of Cognition
•	Kimberley Indigenous Cognitive Assessment
(See Resources)
Opportunistic GPP
Behavioural People with risk 
factors for dementia 
including excessive 
alcohol intake, tobacco 
smoking hypertension, 
diabetes, depression
Management of dementia risk factors is 
recommended for multiple health benefits, 
however, there is limited evidence that this leads 
to a reduction in dementia incidence
Opportunistic GPP
Chemoprophylaxis People without a 
confirmed diagnosis of 
dementia
Anti-dementia drugs are not recommended N/A 1B
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Educational and quitting resources (Centre for Excellence in 
Indigenous Tobacco Control) 
www.ceitc.org.au 
Tobacco in Australia: a comprehensive review of the major 
issues in smoking and health in Australia (Cancer Council 
Victoria)  
www.tobaccoinaustralia.org.au  
Fagerström nicotine dependency test  
www.health.wa.gov.au/smokefree/docs/Fagerstrom_
Test.pdf
Detailed information on tobacco resources, publications, 
programs and projects (Australian Indigenous 
HealthInfoNet)  
www.healthinfonet.ecu.edu.au/health-risks/tobacco
Brief intervention and self help resources to promote 
smoking cessation for Aboriginal people (SmokeCheck) 
www.smokecheck.com.au/about/resources/index.php 
Medicines to help Aboriginal and Torres Strait Islander 
people stop smoking: a guide for health workers 
Email IndigenousTobacco@health.gov.au
Medicines to help you stop smoking: a guide for smokers 
Email IndigenousTobacco@health.gov.au
Supporting smoking cessation: a guide for health 
professionals (RACGP) 
www.racgp.org.au/guidelines/smokingcessation
National Tobacco Campaign including ‘Break the Chain’ 
campaign for Aboriginal and Torres Strait Islander people 
and Quitline (proactive telephone support) information and 
referral forms (Australian Government) 
www.quitnow.gov.au/internet/quitnow/publishing.nsf/
Content/home 
Closing the Gap clearinghouse (AIHW) 
www.aihw.gov.au/closingthegap/documents/resource_
sheets/ctgc-rs04.pdf 
Quitting resources (NSW Health) 
www.health.nsw.gov.au/PublicHealth/healthpromotion/
tobacco/cessation.asp





Growth charts (Centers for Disease Control and Prevention) 
www.cdc.gov/growthcharts/cdc_charts.htm
BMI charts (WHO) 
children 5–19 years  
www.who.int/growthref/who2007_bmi_for_age/en/
index.html 
children under 5 years  
www.who.int/childgrowth/standards/bmi_for_age/en/
index.html





Quick reference guide to the treatment of alcohol problems: 
companion document to the guidelines for the treatment of 
alcohol problems (Australian Government)  
www.alcohol.gov.au/internet/alcohol/publishing.nsf/
Content/treat-quick 
Guidelines for safer alcohol use (NHMRC)  
www.health.gov.au/internet/alcohol/publishing.nsf/
Content/standard




AUDIT-C tool  
www.cqaimh.org/pdf/tool_auditc.pdf
IRIS tool (Queensland Government) 
www.health.qld.gov.au/atod/prevention/iris.asp 
Talking about alcohol with Aboriginal and Torres Strait 
Islander patients flipchart (the flipchart includes tear off 
prescription pads)  
www.alcohol.gov.au




‘Let’s talk about gambling’ (Aboriginal Health and Medical 
Research Council) 
www.aboriginalgamblinghelp.org.au
Gambling Help Online  
Counselling, information and support service for problem 
gambling issues, includes contact details for local face-to-
face counselling and support  
www.gamblinghelponline.org.au 
National problem gambling telephone counselling services  
National Problem Gambling Hotline: 1800 858 858 
Gamblers Anonymous: 1800 002 210
Problem Gambling Research and Treatment Centre  
Guidelines for screening, assessment and treatment in 
problem gambling  
www.med.monash.edu.au/sphc/pgrtc/guideline/index.
html
Chapter 2: Child health
Immunisation
Catch-up immunisation calculator  
www.health.sa.gov.au/immunisationcalculator
Australian Immunisation Handbook  
www.health.gov.au/internet/immunise/publishing.nsf/
content/handbook-home
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Anaemia
Iron deficiency anaemia assessment, prevention and 




Guidelines for community control of scabies, skin sores and 
crusted scabies in the Northern Territory (Northern Territory 




Chapter 3: The health of young people
Illicit drug use
CRAFFT tool for clinicians 
www.ceasar-boston.org/CRAFFT/pdf/CRAFFT_
English.pdf
CRAFFT tool for self administration  
www.ceasar-boston.org/CRAFFT/pdf/CRAFFT_SA_
English.pdf
Substances and choices scale manual 
www.sacsinfo.com/docs/SACSUserManualNoPrint.pdf
Substances and choices scale questionnaires 
www.sacsinfo.com/Questionnaires.html
IRIS (Indigenous risk impact screen) tool and brief 
intervention. The screening tool  
is made available only after participation in a training 
workshop 
www.health.qld.gov.au/atod/prevention/iris.asp
Chapter 4: Dental health
Lift the lip and see my smile brochures (NSW Government) 
www.health.nsw.gov.au/resources/pubs/orderform_
pdf.asp
Information pamphlets for oral health and smoking, erosion, 
diabetes, pregnancy (Dental Practice Education Research 
Unit) 
www.arcpoh.adelaide.edu.au/dperu/special







Learning modules on oral health for health professionals 
(Smiles for Life) 
www.smilesforlifeoralhealth.com
Chapter 5: Rheumatic heart disease
Updated Australian guidelines for diagnosis and 
management of ARF and RHD
(Rheumatic Heart Disease Australia) 
www.rhdaustralia.org.au 
Rheumatic heart disease: all but forgotten. A 60 minute 
program outlining strategies for the treatment, control 
and eradication of ARF and RHD (Rural Health Education 
Foundation) 
www.rhef.com.au/programs/program-1/?program_id=37
Chapter 6: Eye health
Trachoma and trichiasis
Full report on National Indigenous Eye Health Survey 
www.eyefoundation.org.au/projects/research-
projects/89-minum-barreng-project




Patient factsheets on diabetic retinopathy (CERA) 
www.cera.org.au/uploads/CERA_factsheet_
DiabeticRetinopathy.pdf
Guidelines for the public health management of trachoma 




At cost vision screening kits including E-test charts, which 
are suitable for primary care including remote use (CERA) 
www.cera.org.au/our-work/resources/vision-
screening-tools 
Grading card showing the simplified trachoma grading 
system, which includes high quality clinical pictures of 
trachoma and trichiasis (2-sided), available free (WHO) 
www.who.int/blindness/publications/trachoma_
english.jpg
Comprehensive practical documents including control 
program, surgery and community support guides (WHO) 
www.who.int/blindness/causes/trachoma_documents/
en
Chapter 7: Hearing loss
Recommendations for clinical care guidelines on the 
management of otitis media in Aboriginal and Torres Strait 
Islander populations (Darwin Otitis Guideline Group in 
collaboration with the Office for Aboriginal and Torres Strait 




Therapeutic Guidelines: Antibiotics 
www.tg.org.au/?sectionid=41
Noise destroys your hearing (Australian Hearing) 
www.hearing.com.au/upload/media-room/Noise-
destroys-your-hearing.pdf
Chapter 8: Sexual health and bloodborne 
viruses
Bloodborne viral and sexually transmissible infections in 
Aboriginal and Torres Strait Islander people: surveillance 
and evaluation report 2011 (The Kirby Institute) 
www.med.unsw.edu.au/NCHECRweb.nsf/
resources/2011/$file/KIRBY_ATSIP2011.pdf
Sexual health clinical management guidelines (Queensland 
Government)  
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www.health.qld.gov.au/sexhealth/documents/cm_
guidelines.pdf
Clinical guidelines for the management of sexually 




Guidelines for managing sexually transmissible infections 
http://silverbook.health.wa.gov.au/Default.asp?Publica
tionID=1&SectionID=74
Management of genital Chlamydia trachomatis infection: 
a national clinical guideline (Scottish Intercollegiate 
Guidelines Network) 
www.sign.ac.uk/pdf/sign109.pdf
Sexually transmissible infections: UK national screening 
and testing guidelines  
www.bashh.org/documents/59/59.pdf
Drug misuse: psychosocial interventions, national clinical 
practice guideline number 51 (National Collaborating Centre 
for Mental Health) 
www.nice.org.uk/nicemedia/pdf/CG51FullGuideline.pdf
Australasian contact tracing manual (ASHM)  
http://ctm.ashm.org.au/Default.asp?PublicationID=6&P
arentSectionID=P6&SectionID=733





Hepatitis B virus testing and interpreting results (ASHM)  
www.ashm.org.au/images/publications/monographs/b%20
positive/b_positive-chapter_3.pdf
Counsellor’s guide to working with alcohol and drug users 
www.dao.health.wa.gov.au/InformationandResources/
Publicationsandresources/Healthprofessionals.aspx
Drug and alcohol psychosocial interventions professional 




Drug misuse: psychosocial interventions, national clinical 
practice guideline number 51 (National Collaborating 
Centre for Mental Health) 
www.nice.org.uk/guidance/CG51/NICEGuidance
Guidelines for the psychosocially assisted pharmacological 




Chapter 9: Antenatal care
Guidelines for management of diabetes in pregnancy 
(Australasian Diabetes in Pregnancy Society)  
www.ranzcog.edu.au/publications/statements/coll-
end-statements/ADIPS-gdm-management-guidelines
Screening guideline for gestational diabetes (Kimberley 
Aboriginal Medical Services Council) 
http://resources.kamsc.org.au/downloads/cd_dip.pdf
Guidelines for treatment of vitamin D deficiency (King 
Edward Memorial Hospital) 
www.kemh.health.wa.gov.au/development/manuals/
O&G_guidelines/sectionb/1/b1.1.9.pdf
Dietary guidelines for Australian adults (NHMRC) 
www.gofor2and5.com.au/DataStore/files/pdf/n33.pdf
Iodine, public statement: iodine supplementation for 
pregnant and breastfeeding women (NHMRC) 
www.nhmrc.gov.au/_files_nhmrc/publications/
attachments/new45_statement.pdf
Clinical practice guidelines on depression and related 
disorders in the perinatal period (beyond blue) 
www.beyondblue.org.au/index.aspx?link_id=6.1246




Chapter 10: Mental health
Prevention of suicide
Australian Indigenous Mental Health (Royal Australian and 
New Zealand College of Psychiatrists)  
http://indigenous.ranzcp.org
Working together: Aboriginal and Torres Strait Islander 
mental health and wellbeing principles and practice  
www.ichr.uwa.edu.au/files/user5/Working_Together_
book_web.pdf
Chapter 11: Respiratory health
Asthma
British Guideline on the Management of Asthma (British 
Thoracic Society, Scottish Intercollegiate Guidelines 
Network)  
www.sign.ac.uk/pdf/sign101.pdf
Multiple resources including guides to asthma 
management and spirometry (National Asthma Council 
Australia) 
www.nationalasthma.org.au 
International evidence based guidelines and clinical 
resources (Global Initiative for Asthma) 
www.ginasthma.org
Chronic obstructive pulmonary disease




The COPD-X Plan. Australian and New Zealand guidelines 
for the management of chronic obstructive pulmonary 
disease  
www.copdx.org.au 
Inhaler technique in adults with asthma or COPD 
www.clinicalguidelines.gov.au/search.
php?pageType=2&fldglrID=1564&
Chronic obstructive pulmonary disease: diagnosis and 
management of acute exacerbations 
www.guideline.gov/syntheses/synthesis.
aspx?id=16404









Management of chronic obstructive pulmonary disease in 
adults in primary and secondary care (partial update) 
www.guideline.gov/content.aspx?id=23860&search=as
thma+and+prevention
Chronic obstructive pulmonary disease 
http://guidance.nice.org.uk/CG101 
Bronchiectasis and chronic suppurative lung 
disease




Chapter 12: Cardiovascular disease 
prevention
For absolute risk calculation consult:





Calculators embedded in clinical software programs
Framingham Risk Equation calculator 
www.cvdcheck.org.au
For blood pressure and lipid management guidelines 
consult:
Guidelines for the management of absolute cardiovascular 




For oral anticoagulant management recommendations 
consult:
Therapeutic Guidelines: Cardiovascular.
Chapter 13: Chronic kidney disease 
prevention and management
Chronic kidney disease management in general practice, 
2nd edn (Kidney Health Australia)
Caring for Australians with Renal Impairment guidelines  
www.cari.org.au





Chapter 15: Prevention and early detection 
of cancer
Prevention of cervical cancer
Screening to prevent cervical cancer: guidelines for 
the management of asymptomatic women with screen 
detected abnormalities (NHMRC) 
www.nhmrc.gov.au/publications/synopses/wh39syn.
htm 




Prevention and early detection of liver 
(hepatocellular) cancer
The Australian immunisation handbook (NHMRC): hepatitis 
B chapter  
www.immunise.health.gov.au/internet/immunise/
publishing.nsf/Content/Handbook-hepatitisb 
Australia and New Zealand chronic hepatitis B 
recommendations (Gastroenterological Society of Australia 
and Digestive Health Foundation) 
www.gesa.org.au/files/editor_upload/File/Professional/
CHB.pdf
HIV, viral hepatitis and STIs: a guide for primary care 
(Australasian Society for HIV Medicine: further resources 
will be available through ASHM in 2012, including 
information on access to new treatment options for some 
people with chronic hepatitis C infection) 
www.ashm.org.au/default2.asp?active_page_id=133 
Prevention and early detection of breast cancer
Family cancer clinics (Cancer Australia) 
http://canceraustralia.nbocc.org.au/fraboc/clinic.html
Online calculator, familial risk assessment – breast and 




Advice about familial aspects of breast cancer and 
epithelial ovarian cancer (National Breast and Ovarian 




Advice for women seeking advice about risk reducing 




Prevention and early detection of colorectal 
(bowel) cancer
Guidelines for the prevention, early detection and 
management of colorectal cancer used to determine a 
person’s risk of colorectal cancer based on family history 
www.nhmrc.gov.au/publications/synopses/
cp106/cp106syn.htm or summary at www.
cancer.org.au/file/HealthProfessionals/
ClinicalpracticeguidelinesJuly2008.pdf 
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Early detection of prostate cancer
The early detection of prostate cancer in general practice: 
GP/patient show card 
www.cancerqld.org.au/content/Document/The%20
Early%20Detection%20of%20Prostate%20Cancer.pdf 
Let sleeping dogs lie? What men should know before 
getting tested for prostate cancer 
http://ses.library.usyd.edu.au/bitstream/2123/6835/3/
Let-sleeping-dogs-lie.pdf  
Chapter 16: Preventive health for the elderly
Osteoporosis 






RACGP algorithm for the detection, prevention and 












Care of patients with dementia in general practice (The 





Kimberley Indigenous Cognitive Assessment  
www.wacha.org.au/kica.html
General Practice Assessment of Cognition  
www.gpcog.com.au
National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people
Resources
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Appendix 1
Australian cardiovascular risk charts
Heart Foundation Guide to management of hypertension 200816


































































Total cholesterol:HDL ratio* Total cholesterol:HDL ratio*
* In accordance with Australian guidelines, patients with systolic blood pressure ≥ 180 mm Hg,













































































Total cholesterol:HDL ratio* Total cholesterol:HDL ratio*
* In accordance with Australian guidelines, patients with systolic blood pressure ≥180 mmHg,










Non-smoker Smoker Non-smoker Smoker
People with diabetes
Adults over the age of 
60 with diabetes are 
equivalent to high risk 
(>15%), regardless 
of their calculated risk 
level. Nevertheless, 
reductions in risk 
factors in this age 
group can still lower 
overall absolute risk
Charts in this age 
bracket are for use in 
Aboriginal and Torres 
Strait Islander 
populations only
Charts in this age 
bracket are for use in 
Aboriginal and Torres 
Strait Islander 
populations only.








Moderate risk Low risk
10–15%








Moderate risk Low risk
10–15 %
Notes: The risk charts include values for SBP alone, as this is the most 
informative of conventionally measured blood pressure parameters for 
cardiovascular risk.
CVD refers collectively to coronary heart disease (CHD), stroke and other vascular 
disease including peripheral arterial disease and renovascular disease.
Charts are based on the NVDPA’s Guidelines for the assessment of absolute 
cardiovascular disease risk and adapted with permission from New Zealand 
Guidelines Group. New Zealand Cardiovascular Guidelines Handbook: A Summary 
Resource for Primary Care Practitioners. Second edition. Wellington, NZ: 2009. 
www.nzgg.org.nz.
Heart Foundation Guide to management of hypertension 2008 15
Figure 1. Australian cardiovascular risk charts
How to use the risk charts
1.  Identify the table relating to the person’s diabetes status, 
sex, smoking history and age. ‘Smoker’ is defined as 
either current daily cigarette smoker or former smoker 
who has quit within the previous 12 months. The charts 
should be used for all adults aged 45–74 years (and 
all Aboriginal and Torres Strait Islander adults aged 
35 years and older) without known history of CVD or 
already known to be at high risk.
2.  Within the chart, choose the cell nearest to the 
person’s age, systolic blood pressure (SBP) and total 
cholesterol (TC):HDL ratio. For example, the lower left 
cell contains all non-smokers without diabetes who 
are 35–44 years and have a TC:HDL ratio of less than 
4.5 and a SBP of less than 130 mm Hg.
SBP (mean of two readings on two occasions).•	
Total cholesterol/high-density lipoprotein cholesterol •	
(HDL-C) ratio (ensure correct ratio is used).
3.  The colour of the cell that the person falls into 
provides th ir 5-year bsolute cardiovascular risk 
level (see legend above for risk category). For people 
who fall exactly on a threshold betwe n cells, 
use the cell corresponding to higher risk. The risk 
calculator may underestimate cardiovascular risk in 
these groups:
Aboriginal and Torres Strait Islander adults•	
adults with diabetes aged 60 years or less•	
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* In accordance with Australian guidelines, patients with systolic blood pressure ≥180 mmHg,
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60 with diabetes are 
equivalent to high risk 
(> 15%), regardless 
of their calculated risk 
level. Nevertheless, 
reductions in risk 
factors in this age 
group can still lower 
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Charts in this age 
bracket are for use in 
Aboriginal and Torres 
Strait Islander 
populations only.
Charts in this age 
bracket are for use in 
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Strait Islander 
populations only








Moderate risk Low risk
10–15%








Moderate risk Low risk
10–15 %
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Figure 1. Australian cardiovascular risk charts
How to use the risk charts
1.  Identify the table relating to the person’s diabetes status, 
sex, smoking history and age. ‘Smoker’ is defined as 
either current daily cigarette smoker or former smoker 
who has quit within the previous 12 months. The charts 
should be used for all adults aged 45–74 years (and 
all Aboriginal and Torres Strait Islander adults aged 
35 years and older) without known history of CVD or 
already known to be at high risk.
2.  Within the chart, choose the cell nearest to the 
person’s age, systolic blood pressure (SBP) and total 
cholesterol (TC):HDL ratio. For example, the lower left 
cell contains all non-smokers without diabetes who 
are 35–44 years and have a TC:HDL ratio of less than 
4.5 and a SBP of less than 130 mm Hg.
SBP (mean of two readings on two occasions).•	
Total cholesterol/high-density lipoprotein cholesterol •	
(HDL-C) ratio (ensure correct ratio is used).
3.  The colour of the cell that the person falls into 
provides their 5-year absolute cardiovascular risk 
level (see legend above for risk category). For people 
who fall exactly on a threshold between cells, 
use the cell corresponding to higher risk. The risk 
calculator may underestimate cardiovascular risk in 
these groups:
Aboriginal and Torres Strait Islander adults•	
adults with diabetes aged 60 years or less•	
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Figure 1. Australian cardiovascular risk charts
How to use the risk charts
1.  Identify the table relating to the person’s diabetes status, 
sex, smoking history and age. ‘Smoker’ is defined as 
either current daily cigarette smoker or former smoker 
who has quit within the previous 12 months. The charts 
should be used for all adults aged 45–74 years (and 
all Aboriginal and Torres Strait Islander adults aged 
35 years and older) without known history of CVD or 
already known to be at high risk.
2.  Within the chart, choose the cell nearest to the 
person’s age, systolic blood pressure (SBP) and total 
cholesterol (TC):HDL ratio. For example, the lower left 
cell contains all non-smokers without diabetes who 
are 35–44 years and have a TC:HDL ratio of less than 
4.5 and a SBP of less than 130 mm Hg.
SBP (mean of two readings on two occasions).•	
Total cholesterol/high-density lipoprotein cholesterol •	
(HDL-C) ratio (ensure correct ratio is used).
3.  The colour of the cell that the person falls into 
provides their 5-year absolute cardiovascular risk 
level (see legend above for risk category). For people 
who fall exactly on a threshold between cells, 
use the cell corresponding to higher risk. The risk 
calculator may underestimate cardiovascular risk in 
these groups:
Aboriginal and Torres Strait Islander adults•	
adults with diabetes aged 60 years or l ss•	
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AHW  Aboriginal and Torres Strait Islander health  
worker
APSGN  acute post-streptococcal glomerulonephritis
ARF acute rheumatic fever 
BMD bone mineral density 
BMI body mass index 
BPG benzathine penicillin G 
CHD coronary heart disease
CKD chronic kidney disease
COPD chronic obstructive pulmonary disease
CSLD chronic suppurative lung disease
CVD cardiovascular disease 
DALYS disability adjusted life years
DXA dual energy X-ray absorptiometry
eGFR estimated glomerular filtration rate
ESRD end stage renal disease
ETS environmental tobacco smoke
FOBT faecal occult blood test
FPG fasting plasma glucose test 
FRE Framingham risk equation
FVU first void urines
GAS group A streptococcal 
GFR glomerular filtration rate 
GPP good practice points
HAV hepatitis A virus
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HIV human immunodeficiency virus
HPV human papilloma virus
HRCT high resolution chest CT scans
ICS inhaled corticosteroids 
IDA iron deficiency anaemia
IFG impaired fasting glucose
IGT  impaired glucose tolerance 
IPD invasive pneumococcal disease 
IUDs intrauterine devices
LABAs long acting beta agonists
LARC long acting reversible contraception 
MMN multiple micronutrients
MN micronutrients
MRI  magnetic resonance imaging
NAAT nucleic acid amplification tests
NACCHO  National Aboriginal Community Controlled 
Health Organisation
NHMRC   National Health and Medical Research 
Council
NICE   National Institute for Health and Clinical 
Excellence
NRT nicotine replacement therapy
NZGG  New Zealand Guidelines Group 
OCP oral contraceptive pill
OGTT oral glucose tolerance test
PBS Pharmaceutical Benefits Scheme 
PCR protein-creatinine ratio
PCV pneumococcal conjugate vaccine
PEP post-exposure prophylaxis
PIP Practice Incentives Program 
PSA prostate specific antigen 
PVD peripheral vascular disease
RACGP  [The] Royal Australian College of General 
Practitioners 
RBG random blood glucose test 
RHD rheumatic heart disease 
SIGN   Scottish Intercollegiate Guidelines Network
SOLVS  self administered low vaginal swabs
STIs  sexually transmissible infections
TIA  transient ischaemic attacks 
USPTF  US Preventive Services Task Force
UTI urinary tract infection 
VUR vesicoureteric reflux
WHO World Health Organization 


